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ABSTRACT
Differential binding of hnRNP K, L and A2/B1 to an Exonic Splicing Silencer
element located within exon 12 of Glucose-6-Phosphate Dehydrogenase mRNA
Brian Nelson Griffith
The expression of most lipogenic enzymes is regulated through the effects of dietary
polyunsaturated fatty acids on transcription. However, we have observed that the regulation of
Glucose-6-phosphate dehydrogenase (G6PD) by polyunsaturated fatty acids occurs through a
novel posttranscriptional mechanism. RNA reporter assays were used to map the cis-acting
element by measuring the regulation of each RNA reporter construct transfected into primary rat
hepatocytes. All RNA reporter constructs were regulated by polyunsaturated fatty acids with the
exception of RNA reporter constructs lacking exon 12.

Therefore, polyunsaturated fatty acids

regulate the constitutive splicing of G6PD mRNA through a cis-acting element located within
exon 12. Likewise, G6PD expression is regulated by a similar mechanism in intact animals.
Mice fed a high polyunsaturated fatty acid diet inhibit G6PD mRNA expression by 2-4 fold as
compared to a low fat diet. Accordingly, starvation of mice induces a 12-15 fold inhibition of
G6PD mRNA expression as compared to the refed mice.
The proteins that differentially bound to an exon 12 RNA element were observed and
identified in nuclear extracts from starved and refed animals. The cis-acting element was
identified as a region between 50 and 79 nucleotides of exon 12. Identification and purification of
proteins differentially bound to the cis-acting element within exon 12 were identified by LCMS/MS analysis, MALDI-TOF analysis and Western blot analysis. The proteins were identified
as hnRNP K, L, and A2/B1. The 30 nucleotide binding site was further narrowed down to a
region within nucleotides 65-79. HnRNP K, L and A2/B1 were shown to differentially bind in
nuclear extracts of starved versus refed animals and this pattern of protein binding could
potentially regulate G6PD mRNA splicing. All protein identifications were confirmed by
Western blot analysis. Furthermore, a region within nucleotides 65-79 of exon 12 contained a

strong C-rich patch located at nucleotides 65-67 and 69-71 of exon 12. C-rich patches found
within mRNA sequences are thought to be potential binding sites for hnRNP K, L, A2/B1
proteins. The mutation of each of these C-rich patches disrupted protein binding to this region
suggesting that the C-rich patch within 65-79 nucleotides is essential for hnRNP K, L, and A2/B1
protein binding. The binding of hnRNP K, L, and A2/B1 binding to the region of 65-79
nucleotides suggest the presence of an exon splicing silencer sequence within exon 12. The
characterization of protein binding to this exon splicing silencer will be fundamental in providing
new evidence on a novel lipogenic regulatory mechanism by polyunsaturated fatty acids.
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CHAPTER 1
LITERATURE REVIEW
BACKGROUND/SIGNIFICANCE
Significance
Cardiovascular disease associated with heart disease and stroke account for nearly 40%
of all deaths in the United States. According to the Center for Disease Control (CDC),
“cardiovascular disease accounts for nearly one million deaths every year and more then 70
million Americans currently live with cardiovascular disease.” [1] For the last five decades
researchers have been characterizing the relationship between dietary fat and cardiovascular
disease referred to as the “diet heart” hypothesis. The “diet heart” hypothesis has been a central
tenet of strategies for risk reduction in individuals and populations. Individuals have been
encouraged to decrease total dietary fat in their diet and conversely, increase their ratio of
polyunsaturated fatty acids compared to saturated fatty acids within the diet. These
recommendations have resulted in the production of new "low-fat" foods and have changed the
way people think about fat in their diet. However, the molecular pathway by which fat alters
intracellular metabolism is crucial to understanding the molecular basis of cardiovascular
disease, obesity, diabetes, and atherosclerosis. Characterization of these pathways will lead to a
better understanding of diet interaction and risk factors as well as improving strategies for the
treatment of these diseases through drug intervention. Among the intracellular metabolic
pathways affected are those genes involved in lipogenesis and genes involved in cholesterol
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metabolism. Characterization of these pathways affected by polyunsaturated fatty acids will help
to elucidate the pathway in which polyunsaturated fatty acids decrease cardiovascular disease,
obesity, diabetes, and atherosclerosis. Understanding the mode of interaction will also provide
new insight into drug development and possible a better understanding of diet affects on
cardiovascular disease. Therefore we have set out to determine the molecular mechanism of
regulation of one of these lipogenic genes, glucose-6-phosphoate dehdyrogeanse (G6PD) by
polyunsaturated fatty acids.

Fatty Acid Metabolism
Fatty acids synthesized de novo or absorbed in the diet are converted to fatty acyl-CoA
thioesters by acyl-CoA synthetase [5]. Fatty acids converted to fatty acyl-CoAs are bound via
fatty acyl-CoA binding proteins [6]. The final modification of fatty acyl-CoA is to incorporate
those thioesters into various lipids, triglycerides, and phospholipids and/or further oxidize them
into metabolites such as epoxy- or hydroxyl- fatty acids. Some of these downstream metabolites
have direct effects on gene expression. For example, minor phospholipid components of cell
membranes are the phosphatidylinositols, a class of phospholipids, which serve as substrates for
phospholipase C. The products of phospholipase C yield inositol-triphosphate (IP3) and
diacylglycerol, cell signaling molecules [7] . For example, IP3 and diacylglycerol are required
for Ca+2 release from the endoplasmic reticulum. Another class of lipids used for
neurotransmitters are the sphingomyelins and ceramide lipids [8].
An alternative of fatty acid metabolism is the oxidation of fatty acid-CoA molecules by
the cyclooxygenase or lipoxygenase pathway [9]. Arachidonic acid, the main polyunsaturated
fatty acid, is metabolized through the cyclooxygenase and lipoxygenase pathways to give rise to
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prostaglandins and thromboxanes, respectively. Prostaglandins and thromboxanes are autocrine
and paracrine lipid mediators that affect platelet, endothelial, uterine and mast cells among
others. In addition, prostaglandins and thromboxanes act locally through G-protein coupled
receptors to activate intracellular Ca+2 and cAMP levels [10-12]. Therefore, changes in the
overall concentration of these second messengers will lead to changes in the overall gene
expression pattern of a multitude of cell signaling molecules.
The most important fate of fatty acids produced in the diet or by de novo synthesis is βoxidation to produce energy. Fatty acid oxidation is essential for muscle activity and in times of
energy deprivation like starvation or during times of illness. Fatty acid oxidation is essential for
the production and generation of acetyl-CoA molecules during times of starvation. The βoxidation of fatty acids requires the fatty acid to be modified by acyl-CoA synthetase to fatty
acyl-coA thioesters [13]. The fatty acyl-CoA is transferred through the mitochondrial membrane
via carnitine palmitoyltransferase I and II [14,15]. Fatty acyl-CoAs formed from the carnitine
palmitoyltransferse II on the inner face of the mitochondrial are substrates for β-oxidation. The
β-oxidation reactions proceeds step-wise through acyl-coA dehdyrogenase, enoyl-CoA
hydratases, L-3-hydroxyacyl-CoA dehydrogenases, and finally thiolases which convert 3ketoacyl-CoA to acetyl-CoA and an acyl-CoA that reenters the fatty acid oxidation cycle
[reviewed in [16]. Acetyl CoA’s are eventually used to synthesize ketone bodies like βhydroxybutyrate and acetoacetate, which are used as alternative fuel sources for extra hepatic
organs, including the brain during times of starvation.
Fatty acid synthesis is essential during the fed state to store energy within the cell. In
general, a diet high in polyunsaturated fatty acids decreases lipogenesis by repressing gene
expression in the liver
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Table 1: The effect of polyunsaturated fatty acids on metabolic regulation. Modified from [17].

Pathway gene

Transcription
Regulation

Lipogenesis
Stearoyl CoA desaturase 1
Sterol-regulatory element
binding protein
Fatty acid synthase
Acetyl CoA carboxylase
Phosphoenol pyruvate
Carboxykinase (adipose)
Spot 14
Glucose-6-Phosphate
Dehdyrogenase
Fatty acid transport/metabolism
Acyl CoA synthetase
Fatty acid transport protein

Genetic Effects of PolyUnsaturated Fatty Acids

References

YES

[18]

YES
YES
YES
YES

[19-22]
[20,23]
[24]
[25,26]

YES
NO

[23]
[27,28]

YES
YES

[29]
[30]

Energy Utilization/fatty acid oxidation
Carnitine palmitoyl
Transferase-1
Uncoupling protein 1
Acyl CoA oxidase

YES

[31]

YES
YES

[32]
[33]

Cholesterol metabolism
Cyp7α hydroxylase
HMG CoA synthase
ApoCIII
TNFα

YES
YES
YES
YES

[34]
[35]
[36]
[37]

* Abbreviations: Apo, apolipoprotein, Cyp, cytochrome P; HMG,
hydroxymethylglutaryl; HNF-4α, hepatocytes nuclear factor-4 alpha, TNFα, tumor necrosis
factor alpha
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[38]. Conversely, a diet rich in carbohydrates stimulates lipogenesis in both liver and adipose
tissue, leading to elevated plasma triglyceride levels [38]. The inhibition of lipogenic genes in
the liver by polyunsaturated fatty acids is a much stronger signal than insulin stimulation.
Polyunsaturated fatty acid diets in rodents have been shown to inhibit expression of a variety of
genes including those encoding G6PD, acetyl CoA carboxylase (ACC), fatty acid synthetase
(FAS), stearoyl CoA desaturase 1 (SCD1), L-pyruvate kinase (L-PK), Δ-5 and Δ-6 desaturases
in the liver, and insulin-sensitive glucose transporter (GLUT-4) in adipose tissue
[23,24,39,40,40-44]. The regulation of SCD1, ACC and FAS by polyunsaturated fatty acids
occurs at the level of transcription, whereas G6PD is controlled via a post-transcriptional
regulatory mechanism [24,41]. Most lipogenic genes are inhibited by both n-3 and n-6
polyunsaturated fatty acid. An alternative hypothesis is that prostaglandins synthesized by
polyunsaturated fatty acids inhibit lipogenic genes; however, the addition of prostaglandin
inhibitors has limited or no effect on regulation of the lipogenic genes [44,45].

Fatty Acid Regulation of Gene Expression
Polyunsaturated fatty acids are a key control device for fatty acid metabolism within the
cell. Mostly polyunsaturated fatty acids affect gene expression through changes in the
transcriptional rate of the genes of fatty acid transport, energy utilization, fatty acid oxidation,
lipogenesis and cholesterol metabolism (Table 1). Polyunsaturated fatty acids can affect gene
expression by multiple mechanisms but the best characterized are the transcriptional changes in
gene expression. Currently, three different nuclear receptors have been characterized to regulate
gene expression by polyunsaturated fatty acids. The first is the peroxisome proliferator-activated
receptor (PPAR). The PPARs are a steroid hormone nuclear receptor family. The retinoic acid
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receptors (RAR), liver X receptor (LXR) and the ubiquitous retinoid X receptor (RXR) are
members of the steroid hormone nuclear receptor family [46]. Multiple isoforms of PPAR exist
and each isoform of the PPAR family can have different DNA binding sites and thus regulatory
mechanisms to regulate gene expression [46]. Generally, PPAR is an enhancer of fatty acid
transport, energy utilization and fatty acid oxidation genes.
The second main transcription factor is the sterol-regulatory element binding protein
(SREBP). SREBP is a helix-loop-helix family of transcription factors originally identified to
bind the sterol response element found in the genes of cholesterol metabolism [47,48]. Three
main isoforms of SREBP have been isolated and characterized. The first isoform of SREBP is
SREBP-1a, the activated isoform associated with glucose metabolism and insulin metabolism
[47-49]. The second isoform is the SREBP-1c. SREBP-1c is produced from an alternative
spliced mRNA that results in differences in the N-terminal region of these two proteins. The
only difference is the 28 amino acids missing from SREBP-1c that are present in SREBP-1a and
the four unique amino acids present in SREBP-1c. These differences result in differences in
gene regulation. The third isoform is the SREBP-2 protein and it is the most important for
cholesterol homeostasis [47,48,50]. The SREBP family of transcription factors is known to
primarily affect lipid and cholesterol homeostasis.
The last transcriptional factor that regulates lipid metabolism is the hepatocyte nuclear
factor 4α (HNF-4α). The HNF-4α gene is a highly conserved nuclear receptor that modulates
hepatic functions such as cholesterol and lipoprotein secretion [36]. The expression pattern of
HNF-4α is limited to the liver, kidney, intestine, and the pancreas [36]. HNF-4α is an important
transcription factor regulated by polyunsaturated fatty acids, for example polyunsaturated fatty
acids activate HNF-4α through a protein kinase A pathway (Table 1). HNF-4α is a known
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regulator of ApoCIII and Cyp7α hydroxylase through transcriptional changes of ApoCIII and
Cyp7α. HNF-4α is an important transcription factor involved in glucose and lipid metabolism
and as a consequence genetic knockouts of HNF-4α result in diabetes [36].

Transcriptional and Posttranscriptional Regulation of Lipogenic Genes
The family of lipogenic enzymes includes G6PD, fatty acid synthase, acetyl-CoA
carboxylase, stearoyl-CoA desaturase-1, S14, malic enzyme, tricarboxylate carrier and ATPcitrate lyase (Table 1). All lipogenic genes are coordinately regulated with the rate of fatty acid
synthesis. Lipogenic enzymes are regulated predominantly in the liver by the nutritional status
of the animal and G6PD is no exception. The starved state and/or consumption of a diet high in
polyunsaturated fat will inhibit lipogenic genes; however, a diet high in carbohydrates will
increase the activity of lipogenic genes. Inhibition of lipogenic genes by dietary fat is specific
for polyunsaturated fatty acids such as arachidonic acid [3]; in addition, most lipogenic genes are
not regulated by saturated fatty acids [reviewed in 51].
Regulation of the expression of most lipogenic proteins occurs at a transcriptional level
[52,52-59]; however, G6PD is unique because its regulation occurs solely by nuclear
posttranscriptional mechanisms [27,28,60,61]. Incidentally, the malic enzyme [62] and stearoylCoA desaturase [63,64] are also regulated by changes in mRNA stability. The S14 mRNA is
regulated by polyunsaturated fatty acids by a posttranscriptional mechanism, that appears to
involve mRNA processing [65]. In addition the tricarboxylate (citrate) carrier has been shown to
exhibit both transcriptional and posttranscriptional changes due to polyunsaturated fatty acids.
Thus, this supports our contention that other genes may utilize a nuclear posttranscriptional gene
regulatory mechanism similar to our model system of G6PD gene regulation. The absence of
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transcriptional regulation of G6PD makes it an ideal model for studying the nuclear events
involved in regulating pre-mRNA processing by polyunsaturated fatty acids.

Structure of the G6PD gene
The G6PD gene spans 18.5 kb on the X chromosome (xq 28) and contains 13 exons and
12 introns [66,67]. The protein produced from the G6PD mRNA can either contain two or four
subunits per molecule of active enzyme. The protein has an approximately molecular weight of
59 kDa [68]. The G6PD promoter is embedded in a CpG island that is conserved among mice,
rats and humans [66,67]. The promoter of G6PD contains a TATA like element and numerous
stimulatory protein 1 (Sp1) elements, but no CAAT element [66,67,69,70]. The translational
start site of G6PD is located in exon 2 and has been mapped in mice, rats, and humans [66,7173]. The cDNA sequence is greater then 87% identical between mice (Mus musculus) and
humans (Homo sapiens) and greater then 93% identical between rats (Rattus norvegicus) and
mice (Mus musculus). In addition, the number of exons and introns in conserved among species.
There are three main unique characteristics about the G6PD gene. The first feature is the size of
the second intron, 11 kb, which accounts for over half the size of the gene. The second is the
large size of exon 13, 811 nucleotides. The last is the larger than average length of the 3’
untranslated region (3’UTR; 720 nt) 60].

Cellular Role of G6PD
Our studies of G6PD are the first to describe a nuclear posttranscriptional mechanism for
the inhibition of gene expression by polyunsaturated fatty acids [27,28,61]. This
posttranscriptional regulatory mechanism is the only known mechanism for regulation of G6PD
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The Role of G6PD in the Cell

Pentose Phosphate Pathway

Glucose-6-Phosphate
+ NADP+

G6PD

6-Phosphogluconolactone
+ NADPH + H+

Glutathione
Fatty acids

Steroids
Nucleotides

Reductive Biosynthetic
Reactions
Figure 1: A chemical reaction diagram describing the fate of NADPH in the cell
and the role that G6PD plays in the pentose-phosphate pathway.
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expression by nutritional factors. This posttranscriptional regulatory mechanism could possibly
be shared throughout the entire lipogenic gene family, even those genes regulated by
transcriptional regulation. This additional level of regulation would provide a more rapid
response to environmental changes and would allow cells to contain multiple regulatory
pathways to tightly control gene regulation. Glucose-6-phosphate dehydrogenase converts
glucose-6-phosphate to 6-phosphogluconate in the first step of the pentose phosphate
pathwaywhich is the rate-determining step in the pentose phosphate pathway (Figure 1). This
reaction produces reduced nicotinamide adenine dinucleotide phosphate (NADPH), a source of
reducing equivalents for biosynthetic reactions. Another molecule of NADPH is produced when
6-phosphogluconate is oxidized to ribulose-5-pohosphate by 6-phosphogluconate
dehydrogenase. Both enzymatic steps are result in the production of 2 moles of NADPH during
each cycle of the pentose phosphate pathway; NADPH is important for reductive biosynthetic
reactions like fatty acid synthesis, cholesterol synthesis, and amino acid synthesis (Figure 1).
Fatty acid synthesis requires NADPH for the β-ketoacyl-ACP reductase and the enoyl-ACP
reductase reactions in the fatty acid synthesis pathway. The NADPH needed for fatty acid
synthesis comes from both the pentose phosphate pathway and from the malic enzyme. In
mammals, 50% of the NADPH for fatty acid biosynthesis is supplied from the pentose pathway
and the additional 50% from the malic enzyme. In addition, NADPH is also required for the
detoxification of free radicals and peroxides [74,75]. Specifically, NADPH produced by the
G6PD reaction maintains reduced glutathione concentration within the cell. In addition to the
production of NADPH, the pentose phosphate pathway produces ribose-5-phosphate. Ribose-5phosphate is an important precursor for both pyrimidine and purine nucleotide synthesis. In
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general, proliferating cells require an increase in G6PD activity for ribose-5-phosphate
production and NADPH production.
G6PD provides 100% of the NADPH in mature erythrocytes, and in its absence,
erythrocytes are at risk to reactive oxygen species. G6PD deficiencies are among the most
common enzymatic deficiencies [74,76]. Mutations resulting in a decrease in the activity of
G6PD result in chronic, drug and food induced hemolytic anemia in humans [77]. Symptomatic
individuals have a risk of neonatal jaundice and acute hemolytic anemia, triggered by an
infection or the ingestion of certain drugs or fava beans (favaism). Ingestion of primaquine,
sulfonamides, sulfones, nitrofurantoin, vitamin K analogues and some anti-diabetic drugs can
cause symptomatic individuals to have neonatal jaundice and acute hemolytic anemia. A rare
but more severe form of G6PD deficiency is associated with chronic non-spherocytic hemolytic
anemia [78]. G6PD deficiency is also associated with a lack of NADPH production in the liver
thereby decreasing in lipogenic rate resulting in a decrease in serum lipoproteins levels in
affected individuals [79].

Hormonal Regulation of G6PD
Hormones control the expression of all lipogenic genes and G6PD is no exception. For
example, insulin increases the activity of G6PD in intact animals and in cultures of primary rat
hepatocytes [80,81]. Rats treated with streptozotocin, which destroys the pancreatic β-cells, fail
to induce G6PD activity upon refeeding a high carbohydrate diet confirming the requirement for
insulin signaling [82]. In addition, diabetic rats show a decrease in G6PD levels; however,
treatment with insulin induces G6PD activity in diabetic rats [83-85]. Glucagon and cAMP have
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A Model of G6PD Regulation

Figure 2: A model of G6PD regulation by polyunsaturated fatty acids occurs through a nuclear
posttranscriptional mechanism. (A) The change in G6PD protein concentration changes in parallel
to a change in enzyme activity. (B) Protein synthesis changes in parallel to changes in the protein
concentration. (C) The net change in protein synthesis can be accounted for by a change in the
mRNA abundance. (D) The change in mRNA abundance is regulated by a change in the processing
efficiency of the G6PD pre-mRNA.
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the opposite effect compared to insulin because glucagon is a primary hormone of starvation and
thereby decreases the activity of G6PD in starved animals [86].
Other hormones, such as, thyroid hormone (T3) and glucocorticoids regulate
G6PD activity. Thyroidectomy decreases G6PD activity and treatment with T3 induces G6PD
expression. However, the mechanism for this increase does not seem to involve changes in
G6PD mRNA levels [86]. On the other hand, changes in G6PD levels are accompanied by a
similar increase in enzyme synthesis and mRNA abundance [87]. In addition, adrenalectomy,
removal of the adrenal glands, attenuates the increase seen in G6PD activity upon refeeding and
addition of exogenous glucorticoids reverses this effect [reviewed in 88].
A similar G6PD regulation is observed in primary cultures of rat hepatocytes. The
induction of G6PD activity and mRNA level in response to glucose and insulin in hepatocyte
culture mimics the effect observed in intact animals [28,80,81,89,90]. Hepatocytes incubated
with insulin induce G6PD activity 3-4 fold and this increase is accompanied by a parallel change
in the rate of synthesis and mRNA abundance [91]. Glucocorticoids increase G6PD expression
and the addition of glucocorticoids seems to have an additive effect on the insulin induced
increase in G6PD expression [92]. However, T3 and glucagon alone do not change G6PD
activity in cultured hepatocytes [81,93], suggesting that the effect of T3 and glucagon in the
intact animals is an indirect or a compensatory effect.

Regulation of G6PD
G6PD is not only regulated by insulin and glucocorticoids but also by diet. The starved
state and/or consumption of a diet high in polyunsaturated fat (6% safflower oil) will inhibit
G6PD activity [61]. In contrast, a diet that is high in carbohydrates or the refed state will
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increase the activity of G6PD. During the refeeding of a high carbohydrate diet following a 24 h
starvation, G6PD activity increases above the level observed in the animal fed ad libitum
resulting in a phenomenon termed enzyme “overshoot”; the molecular basis for this “overshoot”
is not well understood [94,95]. The high carbohydrate diet consists of glucose or fructose and
the greatest activation of G6PD activity is observed with fructose as compared to glucose alone
[96,97]. The mechanism of action by which glucose increases G6PD activity could be a direct
mechanism of action or indirect mechanism via a change in the redox state of the cell. The
intracellular environment of the cell is much reduced and small changes in the redox state of the
cell could potentially alter the cell environment. In turn these small changes in redox state of the
cell could affect G6PD expression by indirect mechanisms of action. [96,97]. A diet containing
a high ratio of polyunsaturated fat inhibits G6PD activity [98,99]. However, saturated fatty
acids like palmitate (16:0) and stearate (18:0) do not regulate G6PD activity, similar to all
lipogenic enzymes. The addition of polyunsaturated fatty acids seems to inhibit G6PD activity
through a direct mechanism and not by an indirect mechanism of an essential fatty acid
deficiency, or by a decrease carbohydrate intake [98,99]. This inhibition of G6PD by
polyunsaturated fatty acids is only exclusively observed in the liver and adipose tissue [98,99].

Nutritional Regulation of G6PD Expression
The effect of nutrients on the activity, the amount of protein, the rate of synthesis and the
degradation of G6PD has been widely studied. Using antibodies against the G6PD protein and
liver supernatants from rats that were fed a high-carbohydrate diet, the diet-induced increase in
G6PD enzyme activity was shown to parallel the increase in amount of G6PD protein [100,101]
(Figure 2, step A). When examined over a variety of nutritional and hormonal conditions in both
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liver and adipose tissue, changes in G6PD activity could be accounted for by changes in the rate
of enzyme synthesis [84,86,87,100-104] (Figure 2, step B). For instance, a 13-fold increase was
observed in both the relative rate of synthesis for G6PD and the G6PD enzyme activity in the
liver of rats switched from a chow to a high-sucrose diet [87,105]. In addition, the rate of enzyme
degradation is also altered by diet; consumption of a high-fat diet decreases the half-life of the
enzyme from 16 h to 6 h [100]. These changes in enzyme protein turnover will enhance the rate
at which the cell can alter the amount of G6PD activity. Changes observed in the rate of G6PD
protein synthesis due to nutritional or hormonal factors are accompanied by similar changes in
the amount of mature mRNA [27,28,87,92,95,106] (Figure 2, step C). These changes have been
observed during regulation by dietary carbohydrate [87,107], fasting and refeeding [95,106],
dietary polyunsaturated fat [28,108] and hyperthyroidism [87,107] and in rat hepatocytes in
primary culture in response to insulin [28,91,92], glucocorticoids [91,92], and polyunsaturated
fatty acids [61]. These results are consistent with regulation occurring at a pretranslational step
(Figure 2, step D).
During starvation and refeeding, the accumulation of G6PD mRNA in mice occurs after a
lag of 12 h before a two-fold increase is observed [28]. The maximal increase of 27-30 fold is
observed after 24 h of refeeding. In contrast, the effect of dietary polyunsaturated fatty acids is
very rapid. Within 4 h of consumption of a high-fat meal a 20% decrease is observed in G6PD
mRNA amount. The maximal decrease of 80% is observed at 8 h [28]. A similar time course is
observed in primary rat hepatocytes incubated with and without arachidonic acid [28]. This lag
in accumulation of G6PD mRNA during refeeding is consistent with a requirement for the
synthesis of an intermediary protein involved in the induction. A change in mRNA amount can
be due to several factors including transcriptional regulation, processing efficiency of the mRNA
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or degradation of the mRNA. Processing efficiency can be regulated by three separate but
simultaneous events like splicing, polyadenylation, or mRNA capping.
The transcriptional activity of the G6PD gene was measured using nuclear run-on assays
[27]. The rate of G6PD transcription is not regulated by starvation, refeeding a high
carbohydrate diet, or by the inclusion of polyunsaturated fat in the diet [28]. Similar results were
obtained for G6PD regulation by insulin, glucose and arachidonic acid in rat hepatocytes in
primary culture [61]. Furthermore, the transcriptional activity of the G6PD gene occurs at a very
low rate compared to constitutively expressed genes, such as β-actin and GAPDH [27]. The rate
of G6PD transcription is as low as the transcriptional rate of the FAS or stearoyl-CoA desaturase
genes measured during starvation. Upon refeeding, G6PD gene transcription remained at the
same low level despite the 27 – to 30- fold increases in G6PD mRNA accumulation [28].
Similarly, transcription of the gene remains unchanged in mice fed a high-fat diet (6% safflower
oil) despite an 80% decrease in mRNA accumulation [27]. The nuclear run-on assays employed
several controls including probes for both the 5’ and 3’ ends of the gene, as well as, single
stranded probes that would only hybridize to G6PD RNA and not to transcripts produced from
the opposite strand. All probes were free of repetitive elements that could increase the
background hybridization. Together, these results indicate that regulation of G6PD gene
expression by nutritional and hormonal factors occurs at a posttranscriptional step [28] (Figure
2D). Posttranscriptional gene regulation can occur at four steps: the addition of the 7' methylguanosine cap, the formation of the poly (A) tail, splicing, and the export of the mature mRNA
through the nuclear pore complex.
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RNA Processing
The 7-methyl-guanosine cap
Posttranscriptional regulation can occur at many different steps. RNA polymerase II
facilitates the recruitment of processing factors through the C-terminal domain (CTD) [reviewed
in 109]. The CTD provides a scaffold for protein-protein interaction whereby processing
proteins assemble on the transcription apparatus. The CTD contains a tandem heptad repeat of
YSPTSPS throughout the CTD domain [110]. The fifth serine is phosphorylated by the TFIIH –
associated kinase and creates a scaffold domain whereby proteins assemble on the CTD domain
of RNA polymerase II [111,112]. The three characterized binding domains are the CTD
interacting domain [113], the WW domain [114], and the FF domain [115]. Coincident with
transcription of the DNA into RNA the 5’cap is being placed on the message. The first proteins
that assemble on the CTD of RNA polymerase II after transcription are the three capping
proteins, RNA triphosphtase, guanylyl transferase, and the 7-methyltransferase [116,117]. The
5’ cap is a 7 methyl-guanosine structure that is added after transcription proceeds about 20-30 nt
downstream of the transcriptional start site [118,119]. The function of the cap is to prevent 5’
exonucleases from degrading the message [120]. The cap-binding complex (CBC) binds to the
7-methyl-guanosine cap and stabilizes the message by both protecting the cap from decapping
enzymes
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A Model of Splicing

Figure 3: A model of mRNA splicing. RNA splicing involves the binding of U1 and U2 snRNP
to the 5’ splice site and the branch point, respectively prior to recruitment of the tri-snRNP
(U4/U5/U6). The binding of U1 snRNP to the 5’ splice sites and the binding of U2 snRNP to the
branch point help to recruit the U4/U6/U5 tri-snRNP to the spliceosomal complex. U4/U6 and U5
are brought to the B complex and U1 snRNP dissociates, leaving the active C complex to splice out
the intron. Redrawn from [4].
18

Exonic Splicing Enhancer and Silencer Sequences

Figure 4: A diagram representing protein binding to exonic splicing enhancer sequences (ESE) within
an exon. (A) The protein binding of an SR protein (Serine/Arginine protein) is known to bind to ESE’s
and recruit U1snRNP and U2AF35 as well as splicing coactivators like SRM-160. (B) The binding of
hnRNP proteins to ESS sequences inhibits the recruitment of the U1 snRNP and the U2AF65/35 to the
5’ splice site and the 3’ splice site, respectively. Redrawn from [2].
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and by binding to the poly (A) tail. Regulating the 5' cap could regulate gene expression;
however, the addition of the cap occurs within the first 20 to 30 nucleotides thus regulation of the
capping would result in degradation of the message very early in the transcription stage of the
formation of the RNA. For example, the CBC was shown to be activated by heregulin in HeLa
cells by nerve growth factor in PC12 cells, during the G1/S phase of the cell cycle and when
cells are stressed with UV irradiation [121]. In addition, the CBC is a known nuclear target for
growth factor-coupled signal transduction and has provided a new mechanism for the regulation
of capping.
The poly (A) tail
The second possible step for posttranscriptional regulation would be the poly (A) tail.
The length of the poly (A) tail is important for preventing degradation of mRNA transcripts,
which can occur by shortening of the poly (A)-tail via exonuclease and subsequent loss of
interaction between the poly (A) tail binding proteins and the CBC [reviewed in [122]. After the
poly (A) tail is shortened in length, the cap is removed, and then 5’-3’ exonucleases are able to
degrade the mRNA. Degradation of the mRNA is an important regulator of mRNA half-life.
The poly (A) tail is added to the 3’ end of the message to prevent 3’ to 5’ exonucleases from
degrading the message. The addition of a poly (A) tail involves endonucleolytic cleavage of the
3’ terminal noncoding fragment and then polymerization reviewed in [122]. Higher eukaryotes
use either of two signals for polyadenylation; one is the sequence of AAUAAA or AUUAAA.
Either sequence is found about 30 nt upstream of the cleavage site. The other poly (A) site is a U
or a GU- rich region located 3’ of the cleavage site [122]. The mRNA sequence is first cleaved
20-30 nucleotides downstream of a conserved poly (A) site, [reviewed in 109]. Cleavage of
mRNA involves several cleavage/polyadenylation factors (CstF, CPSF, CFIm, and CFIIm) for
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cleavage and polyadenylation, [reviewed in [109]. The second chemical reaction is the addition
of the poly (A) tail at the free 3’ hydroxyl group by poly (A) polymerase, [reviewed in 123]. The
RNA downstream of the cleavage site is still attached to the RNA polymerase and recent studies
have shown the binding of Xm2 to the 5’ region of this RNA and hypothesized that Xm2 is
essential for degradation of RNA downstream of the cleavage site and mRNA release from the
polymerase [124,125].
The poly (A) tail has multiple functions including increasing the efficiency of splicing of
pre-mRNA, transport of mRNA to the cytoplasm increasing translational efficiency, and
cytoplasmic mRNA stability. A message with a long poly (A) tail has a longer half-life than a
mRNA with a short poly (A) tail [126]. Two ideas have suggested that the poly (A) tail protects
the mRNA from degradation. First, the shortening of the poly (A) tail is the initial step in
degradation of the mRNA. Second, the poly (A) tail binds many proteins that protect it from
degradation, such as the poly (A) binding protein described above [127]. Regulation of the poly
(A) tail occurs through the length of the poly (A) tail. A message with a long poly (A) tail has a
longer half-life than a mRNA with a short poly (A) tail [126]. First, alternative
polyadenylation/cleavage signals could be used to change in the length of the 3' untranslated
region included in the mRNA. Second, the length of the poly (A) tail can vary from a few
nucleotides to as many as several hundred nucleotides. The third possibility is that the same
polyadenylation signal is used, but the site of cleavage downstream of the poly (A) site changes
as in the thyroglobulin pre-mRNA [128]. Moreover, hormonal stimuli regulate the
polyadenylation and cleavage site selection and thereby indirectly regulate the length of the poly
(A) tail [128].
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Mechanisms for Splicing
Eukaryotes have a unique structure to their genes called introns, non-coding sequences
with many stop codons and highly repetitive sequences that are removed by intron splicing
events in the nucleus. These introns must be properly spliced before the message can be
transported out of the nucleus [reviewed in [129]. Splicing involves five small nuclear
ribonucleoproteins (snRNPs) U1, U2, U4/U6 and U5 and numerous splicing co-activators (>100)
now known to be essential regulators of both constitutive and alternative splicing (Fig. 3).
Splicing factors are rapidly recruited to nascent transcripts and thus many introns are removed
co-transcriptionally, while others are marked by splicing factors and eventually removed posttranscriptionally [130]. Currently, two different scenarios suggest that splicing factors are
brought to the transcription machinery by the CTD of RNA polymerase II (cf. U1snRNP) [131]
or the that snRNPs are recruited to the RNA through protein-protein interaction independent of
the CTD of RNA polymerase II, cf. [132].
Spliceosome assembly requires a series of interactions prior to the actual spliceosome
assemble. The components that are recruited to the intron are snRNP, which are composed of a
single uridine-rich small nuclear RNA (snRNA) and multiple other proteins. The U1 snRNP
binds the 5' splice site, and the U2 snRNP binds the branch site via RNA: RNA interactions
between the snRNA and the pre-mRNA (Figure 3). The U1 and U2 snRNP help to recruit other
proteins to the spliceosome including the tri-snRNP U4/U6/U5 snRNP, referred to as the
catalytic component of the spliceosome (Figure 3). The final assembly of the spliceosome
requires other proteins whose functions are unknown.
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Serine-Arginine Rich Proteins
The current theory about SR proteins is that they act as splicing co-activators and can be
highly regulated through their phosphorylation state. SR proteins are characterized by an RNA
recognition motif and an SR rich domain [133,134]. SR protein(s) bind to an exonic sequence
and help to directly or indirectly recruit components of the spliceosome to the exon [133-138]
(Figure 4). SR protein binding is essential for splicing of mRNAs with weak consensus
sequences (5’, 3’, branch point, and the polypyrimidine tract). The phosphorylation state of the
SR domain determines the activity of the SR protein. For example, when the SR domain is
phosphorylated the protein becomes active; altering nuclear compartmentalization within the
nucleus. Unphosphorylated SR proteins are predominantly found within speckles within the
nucleus and during phosphorylation they migrate to sites of active transcription [139-142]. SR
proteins can bind to sequences in the exons of the pre-mRNA and aid in the recruitment of
snRNPs to the splice sites [143] (Figure 4). An additional form of regulation is achieved in
alternatively spliced mRNAs by regulating SR protein binding [144].
Exon Definition
The splicing reaction itself has been well characterized, however much less is known
about how splice sites are appropriately paired. RNA sequences must be properly recognized by
RNA binding proteins and therefore the current hypothesis is that recognition occurs through
exon definition. The ‘exon definition model’ applies in most cases, but may not be an absolute
in all splicing events in higher eukaryotes [145]. Sequences around the splice junctions- 5' and 3'
splice sites (5' ss and 3' ss) are clearly important for splice site recognition. However, these
signals appear to contain only about half of the information required for exon and intron
recognition in human transcripts [146]. The sequence or structural context in the vicinity of the
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5' ss and 3' ss motifs is known to play an important role in splice site recognition [147-149].
Additional support for the exon definition model is found through the discovery of exonic
enhancer sequences that help to define an exon [145]. The SR proteins are known to bind these
exon splicing enhancer sites [150]. In addition to binding exon sequences via their RNA binding
domains, the SR proteins also create protein-protein binding via their SR domains with U2AF
35/65 and U1 snRNPs bound to the 5' splice site [151-154]. Such recognition makes the SR
proteins ideal candidates for an exon-bridge complex that helps to define exon splice sites and
also helps in the recruitment of the spliceosomal complex. Therefore, the exon splicing enhancer
sequence serves as a control point for constitutive and alternative splicing events.
Exon Splicing Enhancers
In recent years considerable knowledge has been accumulating on cis-acting elements as
well as on the trans-acting factors that bind them, however little is known about the mechanisms
of splicing regulation [155]. Most mammalian RNA introns are suboptimal, lacking conserved
consensus sequences within splice sites; therefore enhancer sequences are required for splicing.
The lack of strong consensus sequences within the 5’, 3’ splice sites, the branch point and the
polypyrimidine tract would lead to inefficient splicing of those exons flanking that intron. The
polyprimidine tract is located between a branch site and a 3’ splice site (AG) dinucleotide in
mammalian RNA introns; a weak polyprimidine tract contains lots of purines and therefore has a
low binding affinity for the U2AF splicing factor, which is essential for proper splicing. The two
main classes of exon splicing enhancers are the purine rich ESEs and the non-purine rich ESEs.
The purine rich ESEs are usually located downstream of a weak 3’ splice site [156-159]. The
purine-rich ESEs found in mammalian exons consist of a core motif of alternating A’s and G’s,
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generally 6 nucleotides and longer, however an A-repeat or a G-repeat does not function as an
ESE [156-159].
The second class of ESEs is the non-purine-rich ESE. The AC-rich enhancers were first
identified by in vivo selection. AC-rich ESEs have been shown to be involved in the regulated
splicing of both viral and cellular genes. For example, recent studies have shown the protein
binding of the Y box protein (YB-1) to an AC-rich ESE to stimulate the splicing of the CD44
exon [160]. In addition, exonic pyrimidine-rich enhancers have been found in β-globin RNA
[161] and other mammalian RNAs [162,163] .
Exon Splicing Silencers
The identification of exon splicing silencers was a novel discovery made through the
characterization of exon splicing enhancer sequences [150,164-166]. An ESS sequence binds
specific proteins that inhibit the binding of U2AF65/35 to a weak 3’ splice site, thus inhibiting
splicing. ESS sequences are often found connected with ESEs, but can also function upstream
of an ESE [150,163,167]. The proteins most commonly associated with ESSs are the hnRNP
A/B, hnRNP I (PTB), hnRNP K and the hnRNP H protein. These proteins are known to repress
splicing of many exons by binding to UAGG, UCUC, C-rich patches, and poly G motifs,
respectively. These proteins are presumed to function through blocking the earliest steps of the
spliceosome assembly complex [168-170].
Intron Splicing Enhancer and Silencer elements
Intron elements exist as binding sites for regulatory proteins to stimulate or inhibit exon
definition. The intron elements are located within introns and act very similar to ESS or ESE’s.
Intronic splicing enhancers (ISE) and intronic splicing silencers (ISS) are often found in both
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constitutive and alternative spliced mRNAs [171]. Most ISE/ISS sequences are found
surrounded by alternatively spliced exons [172,173]. The function of these ISE/ISS elements is
to bind accessory proteins to facilitate or prevent splicing at nearby splice sites, respectively.
Additional information was achieved through structural analysis of intronic regions surrounding
those alternatively spliced exons. The elements are less well characterized then most ESE/ESS
but recent information on the alternative splicing of the fibroblast growth factor receptor-2
(FGFR2) has identified multiple ISE and ISS elements within introns flanking both exons IIIb
and IIIc [174,175]. Both of these exons in the fibroblast growth factor receptor-2 are
alternatively spliced exons. The regulation of exon IIIb and IIIc splicing is dependent on those
proteins bound to the ISE/ISS within fibroblast growth factor receptor-2 mRNA [174,175].

The family of hnRNP proteins
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are reported to be involved in
multiple aspects of mRNA metabolism [176]. HnRNPs belong to a large family of RNA
binding proteins that are found primarily within the nucleus [177]. However, some hnRNPs are
also involved in nucleo-cytoplasmic shuttling [177]. The movement of hnRNPs between the
nucleus and the cytoplasm could be a form of regulation within the hnRNP family of proteins.
HnRNPs were originally thought to be non-specific proteins that bound to RNA and DNA
irrelevant of sequence specificity. However, hnRNPs have been found to regulate both
constitutive and alternative splicing events. For example, hnRNP L and E2/E1, two members of
the hnRNP family have been shown to regulate the alternative splicing of CD45, a gene involved
in T-cell maturation [170].
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The oldest discovered RNA-binding factor, hnRNP K, is involved in a multitude of
processes including transcriptional control of gene expression, mRNA processing, as well as
translational control mechanisms [178-181]. The mode of interaction with RNA seems to lie
within its KH domain as a site for nucleotide binding [178]. The hnRNP K protein contains
three K homology domains (KH) that mediate RNA binding through C-rich patches within the
RNA sequence [182-184]. The unique feature of hnRNP K is its ability to become
phosphorylated in response to insulin, Erk, protein kinase Cδ, as well as other factors [185-187].
As such, hnRNP K has the potential to sense and integrate signals from multiple kinase cascades
and to generate output targeting factors that regulate nucleic acid-dependent processes [186].
The hnRNP L protein was first discovered as a abundant nuclear protein associated with
lampbrush chromosomes [188]. Traditionally, it was thought that hnRNP L served as a more
global regulator of translation, and mRNA stability and was not thought to play a role in mRNA
splicing. For example, hnRNP L was shown to regulate the translation of the internal ribosomal
entry site within hepatitis C virus [189]. HnRNP L was shown to affect mRNA stability of the
vascular endothelial growth factor and the glucose transporter 1, specifically [190,191].
Recently, hnRNP L was shown to induce the splicing of the nitric oxide synthase pre-mRNA and
conversely to inhibit the alternative splicing of the human CD45 mRNA [170,192,193].
Although the mechanisms by which hnRNP L affects splicing have yet to be elucidated, the
ability of hnRNP L to regulate constitutive and alternative splicing shows the functional diversity
of hnRNP L.
The most abundant hnRNPs belong to a family of A/B proteins. These two family
members are composed of multiple and unique isoforms. The family of A/B proteins is
composed of four main proteins referred to as hnRNP A1/A1B, A2/B1, B2 and A3. The hnRNP

27

A/B family includes paralogous which means that these proteins are derived from two different
genes on different chromosomes. The paralogs within the A/B family consist of A0, A1, A2,
and A3 and three of these forms have multiple isoforms, for example hnRNP A2. The protein
HnRNP A2 is an isoform of hnRNP B1 created through alternative splicing [194]. The hnRNP
A2 gene is located on chromosome 7p15 and contains 12 exons of which exon 2 is alternatively
spliced to give rise to hnRNP B1 protein. The only sequence difference in B1 and A2 is a 12
amino acid insertion at amino acids 3-14 [195]. In addition the two proteins, A2 and B1 are both
highly similar to the hnRNP A1 family member [195,196] . The great diversity within the
hnRNP A/B family members yet each protein is very similar to other members of the same
family provides flexibility in the regulation of gene expression.
The hnRNP A1 protein has been the most studied member of the hnRNP A/B family.
For example, the appropriate binding site of hnRNP A1 has been shown by systematic evolution
of ligands by exponential enrichment (SELEX) and was identified as UAGGGA/U [176].
HnRNP A1 not only can bind to mRNA via a UAGGG sequence but can also facilitate as a
protein scaffold to recruit other proteins to the ESS sequence forming a large macromolecule
complex called the hnRNP complex [155].
Another hnRNP family member is hnRNP I, also known as polyprimidine tract binding
protein (PTB). HnRNP I has been projected to be a comprehensive inhibitor of weak or
regulated exon splicing [197]. HnRNP I binds to a UCUU sequence separated one or more
pyrimidines [198,199]. The regulation of hnRNP I and the diversity hnRNP I is difficult to fully
elucidate because hnRNP I can act not only as a silencer protein but can also act as an enhancer
[200-202]. Moreover, Wagner and Garcia Blanco have suggested that hnRNP I acts as a general

28

repressor of all weak exons, including those pseudoexons, and could play a role in constitutive
splicing [197].
The hnRNP H family includes the hnRNP F, H, H’, and 2H9 proteins [203]. HnRNP H
has been shown to act as both a splicing repressor and activator. For example, hnRNP H can
promote the inclusion of the c-src exon N1 in neuronal cells by binding to an ISE [204].
Conversely, the hnRNP H acts as a powerful splicing repressor in the rat β-tropomyosin (β-TM)
gene by binding to the UGUGGG motif and causing exon 7 skipping in nonmuscle cells [205].
Identification and characterization of new members of the hnRNP family members increases the
complexity of the information we already have on the members of the hnRNP family members.
For example, current evidence about the hnRNP H family suggest they can act as both a
repressor of exon inclusion and an activator of exon inclusion depending on sequence specific
binding within exons or introns.
The last main class of hnRNP proteins is the hnRNP G members which are unique to the
hnRNP family. HnRNP G is encoded by two genes located on the Y chromosome and is only
expressed in the germline cells of the testis [206]. In addition to the role hnRNP G protein plays
in splicing regulation of two mutually exclusive exons in the α-tropomyosin 3 gene, hnRNP G
has been shown to promote skipping of the skeletal muscle (SK)-specific exon and to enhance
inclusion of the nonmuscle (NM) exon [207]. The family of hnRNP family members is not
exclusive to those discussed in this review but currently there are approximately 27 members of
the hnRNP family ranging from hnRNP A to Z family members. However, hnRNP family
members are a functionally diverse class of proteins that seem to be involved in different
processes like replication, transcription, and translation as well as RNA transport and therefore at
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this present time the hnRNP A, B, F, G, H, I, L, K are the best documented and characterized
proteins involved in regulated mRNA splicing.
Regulation of RNA splicing by Exon Splicing Enhancers and Silencers
The regulation of constitutive and alternative splicing is controlled through trans-acting
factors associated to exon splicing enhancers or silencers. Currently, there are two models of
how these cis-acting sequences control splicing. First, an ESE-dependent RNA splicing
mechanism is thought to regulate mRNA splicing by regulating the binding of SR proteins to an
ESE site. The SR protein recruits U2AF-35 and U2AF-65 via its SR domain. In this model the
U2AF-35 serves as a bridge complex between the SR protein and U2AF65 [208,209]. The
second published model is an ESE competition model. Here the ESE sites compete with the ESS
site for protein binding partners [210]. For example, the HIV-1 tat exon 2 contains two protein
binding sites for SC35 and hnRNP A/B proteins (hnRNP A1 & A2; [211]. The binding of the
SC35 protein to the SC35 binding site overlaps the proximal binding site for hnRNP A1 [211].
Therefore, the regulation of hnRNP A/B binding and SC35 protein binding in turn regulate each
other through juxtaposed binding sites. In this model the ESE site competes for protein binding
with the ESS site and depending on the composition of proteins bound to the ESE or ESS the
splicing is enhanced or silenced, respectively. This model is further supported by ESS deletions
within a spliceable construct that activates splicing even in the absence of an ESE binding
protein. [150].
In constitutive splicing, SR proteins have been proposed to promote cross-talk between
neighboring exons by promoting the recruitment of snRNPs activating the spliceosome [154].
As far as alternative splicing is concerned, SR proteins have been shown to bind ESEs and
enhance the splicing of adjacent introns [212,213]. Consequently, SR proteins can also serve as
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silencer proteins as in the case of CD45, where inclusion of three alternative exons (A, B and C)
is regulated upon T cell activation and is dependent on SR protein interaction with an ESS
[212,213]. However, most SR proteins bind ESE sites and assist the binding of U2AF35 and
thus increase splicing efficiency of the constitutive or alternative spliced exon [135,161,214].
The regulation of splicing involves a multitude of pathways but the best characterized is the
through activation of SR proteins. For example, insulin stimulates SR protein phosphorylation
and thus increases the alternative splicing of protein kinase C, a downstream target of insulin
signaling [215-217]. All of these events serve to regulate alternative and constitutive splicing as
is the case for thymidylate synthase. Thymidylate synthase is regulated during the cell cycle by
changes in the rate of splicing of one intron [218]. Another example of constitutive splicing
regulation is G6PD which seems to be regulated by polyunsaturated fatty acid by the splicing of
intron 11 or 12 [3].
RNA quality-control mechanisms
Eukaryotic cells exhibit quality-control mechanisms that recognize and degrade mRNA
that have not completed nuclear pre-mRNA processing or that fail to encode an accurate
polypeptide to the gene sequence [219]. Such aberrant mRNAs are degraded rapidly,
presumably before the accumulation of deviant protein products that could have adverse effects
on the cell. MRNAs that contain premature termination codons are degraded within the cell by
nonsense mediated decay (NMD) [219]. Nonsense mediated decay can occur at two sites within
the cell. The first site of degradation is presumed to occur within the nucleus at the site of
transcription [220,221]. The second site of degradation occurs within the cytoplasm after the
ribosomes bind to the mRNA to be translated and requires three main proteins, Upf 1, 2, and 3
[222-224]. However, the recognition of an mRNA as a nonsense-containing mRNA can affect
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splicing, abundance of the nuclear mRNA pool, and retention of transcripts at the site of
transcription [225]. Understanding these issues should define the pathways of NMD in the cell
and reveal a novel aspect of mRNA biology in eukaryotic cells.
The Molecular Pathway of Nonsense Mediated Decay
RNA that is incompletely spliced or processed is degraded within the nucleus
[220,221,226]. Degradation within the nucleus can occur by multiple mechanisms including the
NMD pathway and the nuclear exosome pathway. Nonsense mediated decay has been shown to
occur in yeast (S. cerevisiae) [227-229] and higher eukaryotes [223].
Deficiency in the NMD pathway can lead to alterations in the genome and eventually
disease, for example β-thalassemia, which is a heritable anemia due to a nonsense mutation
within the β-globin gene [230]. The recognition of a nonsense codon takes place by a
surveillance system during translation of the β-globin mRNA. The NMD pathway in higher
eukaryotic organisms involves a similar mechanism as in yeast. Nonsense-mediated decay is
initiated by the removal of the 7-methyl cap, and 5’ Æ 3’ decay of the mRNA by exonucleases
[reviewed in [223].
The major importance of a cell based surveillance system is to prevent aberrant or
truncated proteins from being produced that would have a deleterious effect [231-233]. For
example, the NMD pathway is essential to maintain the genetic code and a few examples where
mutations within genes cause NMD are the human triose phosphate isomerase [234,235], the
hamster dihydrofolate reductase, and T-cell receptor β-transcript [236,237].
Incomplete splicing of RNA sequences results in degradation of RNA by the NMD
pathway. A requirement for recognition of the NMD pathway is the presence of at least one
intron downstream of the nonsense codon [238]. It has been proposed that splicing of the 3’
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most intron from the human triose phosphate isomerase gene pre-mRNA “marks” the 3’ most
exon-exon junction of the mRNA product so that only nonsense codons located more than 50-55
nucleotide upstream of the “mark” can mediate mRNA decay [238]
Despite the evidence that NMD involves the translation machinery, most premature
termination codons (PTC) containing mRNAs in metazoans are eliminated prior to their release
from the nucleus [reviewed in [223,233]. Models put forward to explain how NMD could
influence mRNA levels in the nuclear fraction of the cell include: (1) cotranslational export and
(2) nuclear scanning. Both of these models depend on the existence of a “mark.” The
cotranslational export model contends that cytoplasmic ribosomes can trigger NMD before a
PTC mRNA has completely transversed the nuclear pore; therefore, lower PTC levels are
detected in the nuclear fraction even though NMD is technically occurring in the cytoplasm
[reviewed in [129]. In contrast, the nuclear-scanning model necessitates the existence of a
nuclear frame reader, possibly nuclear ribosomes, which is contrary to the widely accepted belief
that only the cytoplasmic translation machinery is capable of detecting and responding to an
ORF [reviewed in [129]
Recent observations by fluorescent in situ hybridization have concluded quantitatively
and qualitatively that mRNA that has a premature reading frame termination accumulates at the
site of transcription. TCR-β gene constructs containing premature termination codons were
shown to accumulate near the site of transcription [129,239]. Therefore, two possibilities have
been proposed to answer the question of what are the components of the nonsense mediated
decay pathway. The first possibility is through the recognition by translation machinery in the
nucleus. The possibility of nuclear translation has been rekindled by the discovery of charged
tRNAs and translation initiation factors in the nucleus [240]. Furthermore, nuclear ribosomes
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actively undergoing translation have been identified [241]. Additional evidence that NMD
involves translation machinery includes its requirement for the initiator AUG in a transcript
undergoing nonsense mediated decay and a decrease in nonsense mediated decay with protein
synthesis inhibitors [242].
An alternative to the NMD pathway is the nuclear exosome pathway whereby RNAs are
degraded by riboexonucleases. Incomplete processing of mRNA by defects in capping, splicing
or polyadenylation leads to degradation of mRNA transcripts by the nuclear exosome pathway
[243]. The nuclear exosome is composed of nine 3’->5’ riboexonucleases that appear to function
in both the nucleus and the cytoplasm. Current studies indicate that RNA binding proteins play
an essential role in activation of the nuclear exosome. For example AU-rich elements in the 3’
UTR destabilize the mRNA by activating the nuclear exosome pathway [244]. The nuclear
exosome is a separate nuclear complex with its major constituent being Rrp6p, a 3’->5’
riboexonuclease [243,245,246]. An alternative function of the nuclear exosome is found in the
nucleolus where its main role is in degradation of rRNA molecules [243]. The function of the
nuclear exosome seems to be in surveillance of pre-mRNA that fail to complete splicing, 3’ end
formation, and transport of the mRNA out of the nucleus [243].
The NMD pathway and the nuclear exosome pathway serve as a surveillance mechanism
to monitor RNA processing in order to ensure proper coding of the genetic material. Therefore,
if a message was incompletely spliced or transported then the NMD or nuclear exosome pathway
would degrade that message before it was translated into protein. Inefficient spliced mRNAs
generated by incomplete splicing by both alternative and constitutive splicing would degrade
these aberrant mRNAs presumably by the NMD pathway.
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Identifying the Mechanism for the Posttranscriptional Gene Regulation of G6PD
Current research in our laboratory is to define the mechanism for the posttranscriptional
regulation of G6PD. The components of RNA processing and pre-mRNA are associated with an
insoluble portion of the nucleus referred to as the “nuclear matrix”. The nuclear matrix was
isolated in order to measure differences in the rates of accumulation of mature mRNA and premRNA during RNA processing [60]. In this regard, changes in G6PD mRNA in the cytoplasm
are accompanied by similar changes in the amount of nuclear matrix pre-mRNA while there is
no change in transcriptional activity of the gene [60]. The nuclear matrix fraction is a fibrous
fraction that is thought to contain processing factors including those involved in splicing.
Specific probes were used that crossed intron-exon boundaries in order to measure the
amount of more processed versus less-processed mRNA for G6PD [60]. A change in the amount
of less processed RNA was measured as exon 2-intron 2 and exon 9-intron 9 protected fragments
[60]. The amount of more processed RNA was measured as exon 2 and exon 9. The amount of
mRNA in the cytoplasm accompanied similar changes in the amount of nuclear RNA. These
results suggest that processing efficiency is regulated through controlling the rates of splicing of
G6PD mRNA [60]. Using probes that cross 2 intron/exon boundaries permit the detection of
partially spliced RNA [60]. Feeding a high-carbohydrate diet increased the abundance of G6PD
pre-mRNA in the nuclear matrix fraction. These results suggest that once again the processing
efficiency is changed during the feeding of a high-carbohydrate diet [60]. The amount of spliced
RNA compared to unspliced RNA was 5 fold higher in the mice that were refed as compared to
the mice that were starved [60]. The data suggests that dietary carbohydrate regulates the
efficiency of processing of the pre-mRNA. However, this could be due to changes in the
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Figure 5: A chart representing the constructs transfected into rat hepatocytes
and each constructs relative rate of inhibition. The constructs contained the
CMV promoter in red and the G6PD 3' UTR in teal. The genomic portions of
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efficiency of splicing or 3’ end formation. The extent of polyadenylation was measured using a
probe that binds across the poly (A) signal and the cleavage site within the mRNA. The length
of the poly (A) tail was measured using RNase H assays, to determine if there is a change in the
length of the poly (A) tail during starvation and refeeding (data not shown). The rate of
accumulation of polyadenylated RNA could not account for the high rates of accumulation of
mature G6PD mRNA [60]. Furthermore, the length of the poly (A) tail was not affected by
starvation or refeeding [60]. Changes in protein levels observed with dietary manipulation must
be due to a changes in the mRNA accumulation in the nuclear matrix fraction by a regulated
constitutive splicing event [60].
An alternative dietary manipulation of adding polyunsaturated fat to the diet decreases
the abundance of G6PD mature mRNA by 50% or more in the cytoplasm and in the nucleus,
consistent with a nuclear regulation of gene expression [27]. The abundance of G6PD premRNA was similar during the first 2 h of the daily eating cycle in mice fed either the low-fat or
the high-fat diet. Yet, the amount of mature G6PD mRNA was inhibited in mice consuming the
high-fat diet [3]. The abundance of pre-mRNA increased after 4 h of the low-fat diet and this
increase was attenuated by the high-fat diet. These results suggest that polyunsaturated fatty
acids decrease the processing efficiency of G6PD pre-mRNA [60].
To determine the potential regulatory sequence in G6PD pre-mRNA, we have used RNA
reporter constructs containing various portions of the G6PD gene and transfected these
constructs into rat hepatocytes [3]. The amount of reporter RNA was measured after incubation
of the cells with or without arachidonic acid. RNA produced from constructs containing intron 6
through the end of the G6PD gene was decreased in cells incubated with arachidonic acid [3];
Figure 5]. In contrast, RNA expressed from the G6PD cDNA construct (lacking introns) was not
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inhibited by arachidonic acid; therefore, this regulation is consistent with the need for splicing.
The removal of introns and exons from the 5' end of the RNA reporter constructs did not
abrogate regulation until exon 12 was removed from the transfected constructs [3; Figure 5].
Furthermore, the region of DNA from exon 12 through the end of the gene could confer
regulation of RNA amount onto the heterologous mRNA, beta-galactosidase and the G6PD
cDNA [3]. Additional experiments in intact mice support these findings. In the livers of mice
fed a high-fat diet, pre-mRNA retaining intron 11 accumulates in the nucleus while the amount
of mature G6PD mRNA in the cytoplasm is decreased 50% or more [3]. Thus, exon 12 contains
a potential exon splicing enhancer sequence. Current experiments in this project involve the
precise mapping of proteins to exon 12.

Our Current Model for the Regulation of G6PD
The dietary paradigm of starvation and refeeding results in a robust change of 12-15 fold in
G6PD mRNA expression. The change in G6PD mRNA accumulation can be accounted for by a
change in the splicing efficiency of the pre-mRNA. A cis-acting element has been localized to
exon 12 of the G6PD mRNA sequence using RNA reporter constructs transfected into primary
rat hepatocytes. Therefore exon 12 was predicated to contain either an ESE or an ESS element
within exon 12 (Figure 6). The protein binding of an SR protein by insulin (primary rat
hepatocytes) or refeeding would result in the recruitment of the U1snRNP and U2AF35/65 to the
5’ and 3’ splice site, respectively. The SR protein would serve to enhance splicing of the G6PD
pre-mRNA during the presence of insulin (primary hepatocytes) or refeeding (Figure 6). The
large changes observed in animals refed would suggest that this protein would be regulated by
the insulin signal transduction pathway. The presence of fatty acids (primary hepatocytes) or
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starvation would result in a decrease of G6PD processing efficiency. The decrease in splicing
could be mediated through an ESS element within exon 12. The binding of essential proteins to
the ESS element would inhibit the splicing of G6PD mRNA. The incompletely spliced mRNA
would be degraded by the NMD or the nuclear exosome pathway. The identification of proteins
bound to either an ESE or an ESS would facilitate a novel discovery of nutritional regulation of
G6PD mRNA. Crucial to the proof of this mechanism is the identification of those relevant
nuclear proteins involved in the regulation of G6PD RNA splicing.
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G6PD Regulation
Refeeding

Starvation

Figure 6: Our model of G6PD mRNA regulation occurs through the
presence of an ESE and an ESS within exon 12 of G6PD mRNA. Intact
animals fed a refed a high carbohydrate diet would bind an SR protein and
increase the splicing efficiency of introns 11; however, starvation would
result in the binding of hnRNP proteins to an ESS sequence and introns 11
would not be properly spliced and thereby would be degraded within the
nucleus presumable by the non-sense mediated decay pathway.
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Chapter 2
Development of Techniques to Identify RNA Binding
Proteins
The following data in this chapter (Figures 1, 3, 4, and Table 1) were incorporated into a
manuscript recently published in the Journal of Biological Chemistry. Szeszel-Fedorowicz W,
Talukdar I, Griffith BN, Walsh CM, Salati LM. An exonic splicing silencer is involved in the
regulated splicing of glucose 6-phosphate dehydrogenase mRNA. J Biol Chem. 2006 Nov
10;281(45):34146-58. Epub 2006 Sep 15.
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Development of Techniques to Identify RNA Binding
Proteins
SUMMARY
Isolation of proteins that specifically interact with a given RNA regulatory element is
essential for studies on the molecular mechanisms of gene expression. RNA affinity purification
protocol that consists of an RNA oligo bound to adipic-acid agarose beads. The RNA oligo is
covalently bound via the free 3’ hydroxyl group to sodium periodate treated adipic acid
dihydrazide-agarose beads. The bound proteins are run on SDS–PAGE and colloidal Coomassie
stained protein bands are cut out and subjected to trypsin digestion prior to mass spectrometry
(MS) analysis. Using this method, hnRNP K, L, I, E1, and A2/B1 proteins were found to be
associated with the glucose-6-phosphate dehdyrogenase (G6PD) mRNA exon splicing silencer
sequence (ESS) located within nucleotides 43 to 72 of exon 12. The ability of this assay to
differentiate such small RNA sequences will help define RNA regulatory sequences and their
respective protein binding partners. RNA affinity purifications schemes have often used long
RNA sequences; however, we have used 15 nucleotide RNA oligos to purify essential proteins.
RNA oligos were used in a RNA affinity assay to purify specific proteins bound to RNA oligos.
The RNA oligos were able to successfully purify several HeLa cell nuclear extract proteins,
heterogeneous nuclear ribonuclear protein (hnRNP) K, L, I, E1 and A2/B1, bound to the
conserved exon splicing sequence within exon 12 of G6PD mRNA.
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INTRODUCTION
The interaction of RNA binding proteins with their RNA targets plays a critical role in
RNA processing [1], polyadenylation [2], nuclear exit [3], RNA interference [4-6], and
cytoplasmic RNA degradation [7-9]. Qualitative methods for initial identification of RNAprotein interactions such as immunoprecipitation, and tag-based methods, such as tandem
affinity purification have undergone significant evolution in the past few years [10,11].
However, a method that provides accurate identification of proteins bound to 15 nucleotide
oligonucleotides (oligos) will facilitate the purification and identification of only a subset of
proteins bound to RNA sequences. This method facilitates the covalently binding of short RNA
oligos to adipic acid dihydrazide-agarose beads prior to purification and identification with
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis, Matrix-Assisted
Laser Desorption/Ionization-Time of Flight (MALDI-TOF) Mass Spectrometry Analysis and
Western analysis. In order to validate this method we will perform protein purification and
identification by evaluating the proteins bound to an exonic splicing silencer sequence (ESS)
found within exon 12 of G6PD mRNA. G6PD is posttranscriptionally regulated by an exon
splicing silencer located within exon 12 and identification of proteins bound via this ESS will be
fundamental in characterization of a novel gene regulatory pathway [12,13].
In this report, we present evidence that hnRNP K, L, I and A2/B1 proteins are bound to
the ESS1 site within exon 12. Using the modified approach we have identified a region of G6PD
exon 12 mRNA from nucleotides 65-79 essential for hnRNP K, L, I, A2/B1 binding; however,
purification of these proteins required a 30 nucleotide RNA element corresponding to
nucleotides 50-79 of exon 12. These data are consistent with a role for these proteins in
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silencing the splicing of G6PD pre-mRNA. The identification of these regulatory proteins
provides new information on the breadth of mechanisms by which hnRNP proteins are involved
in constitutive splicing of G6PD mRNA.

METHODS
Cell growth and nuclear extract preparation
HeLa cells (American Type Culture Collection, Rockville, MD) were grown in MEM
medium containing 10% heat inactivated fetal bovine serum. Nuclear extracts from HeLa cells
were isolated by a modification of the Dignam protocol [14,15]. All buffers contained 0.1 mM
phenylmethylsulfonyl fluoride (PMSF) and 0.5 mM dithiothreitol (DTT). Nuclei were extracted
in 350 mM KCl in the presence of protease inhibitor cocktail COMPLETE (Roche). Aliquots of
the extracts were frozen and stored at –80oC. Protein concentrations were determined using the
Bradford assay (Bio-Rad) and were typically in the range of 1-2 μg/μl. HeLa cell nuclear
extracts were also purchased from Promega and ProteinOne.

In vitro transcription of RNA substrates
Plasmid E12 contained the 93 nucleotide exon 12 of G6PD mRNA and was generated by
the PCR using the 5’ primer AATAAGCTTTGATGAACTCAGGGA and the 3’ primer
ATTTCTAGACTGCCATATACATAG. The 5’ primer contained a HindIII restriction site and
the 3’ primer contained an Xba1 site. The PCR amplified insert was subcloned in pKS+ vector
(Stratagene) using the corresponding restriction sites. Probes were either gel purified or purified
using sephadex G50 spin columns (Amersham). Exon 12Δ1 probe (nucleotides 56-93 of exon
12) was created using the PCR with the following 5’ primer
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ATAAAGCTTCTGCTGCACAAGATTGAT and the 3’ primer ATTTCTAGACTGCCAT
ATACATAG to generate an insert that was subcloned into the pKS+ plasmid. Exon 12Δ2 probe
(nucleotides 66-93 of exon 12) was generated with the same 3’ primer and the following 5’
primer TGAAAGCTTATTGATCGAGAAAAGCC and the amplified fragment was inserted into
pKS+ plasmid. All PCR purified inserts were produced from a HindIII/HindIII insert of G6PD
genomic DNA. The purified products were sequenced and the sequence was verified with the
NCBI database sequence of G6PD (BCOOO337).
The RNA probes were synthesized with T3 polymerase to generate the RNA strand as
described [16]. Briefly, plasmids were linearized with appropriate restriction enzymes, RNA
templates were transcribed with T3 RNA polymerase in the presence of 500 mM (each) ATP,
UTP, and GTP; 50 mM CTP; and 50 μCi of α32P-CTP (MP Biomedicals). RNAs were gel
purified by separating them on a 5% denaturing polyacrylamide gel. RNA was visualized by
autoradiography and probes were cut from the gel and purified by crushing and extracting them
in RNA extraction buffer (Ambion). RNAs were purified with 1/10 volume of 5 M sodium
acetate and 2.5 volumes of 100% ethanol at –20oC for 1 h followed by centrifugation at 10,000 g
for 30 min at 37oC. The purified RNA was dissolved in EB buffer (Qiagen) and the activity of
the RNA probe was measured using a scintillation counter.

RNA Oligos
The RNA oligos (IDT) correspond to 15 nucleotide regions of exon 12 G6PD mRNA.
The RNA oligos corresponded to nucleotides 50-64, 65-79 and 79-93. Two RNA oligos were
designed as positive and negative controls. RNA oligo, hnRNPA1 was designed to contain the
following sequence UAGGGACUUAGGGUG based upon known data of hnRNPA1 high
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affinity binding sites [17]. The negative control oligo was a non-specific oligo that was
predicted by the ESE database http://exon.cshl.edu/ESE [18] and the ESS data bases,
http://genes.mit.edu/fas-ess [19], and http://cubweb.biology.columbia.edu/pesx [20], to have
limited protein binding sites and the sequence of the non-specific oligo was
CAAAAGCAUGCAAAA. An additional 30 nucleotide oligo was designed to nucleotides 50-79
of exon 12 to increase the quantity of protein bound by decreasing steric hindrance between the
protein and the adipic acid beads. RNA oligos were labeled with γ-P32-ATP using a kinase Max
kit (Ambion). Briefly, RNA oligos were incubated with 1X kinase buffer (Ambion) with γ-P32ATP (7,000 Ci/mmol) (MP Biomedicals) for 1 hr at 37oC. Unincorpated nucleotides were
removed using a Sephadex G50 spin column [17] (Amersham BioScience) according to the
manufacturer’s protocol.

UV crosslinking
UV cross-linking reaction mixtures contained 5 to 10 μg of nuclear extract, 10 to 20 fmol
of substrate RNA (50,000 to 100,000 cpm), 1 mM ATP, 0.7 mM MgCl2, and 40 ng of carrier
tRNA, brought to a 25-ml final volume with nuclear extract dialysis buffer [15]. Reaction
mixtures were incubated for 5 to 10 min at 30oC and then subjected to UV cross-linking on ice
for 10 min in a Stratalinker (1.8 x 106 mJ/cm2). In vitro transcribed RNA probes were treated
with RNase A (1mg/ml) for 15 min at 37oC. Reactions with RNA oligos were not treated with
RNase A. Proteins were boiled for 5 min in cracking buffer (80 mM Tris-HCl, pH 6.8, 0.1 M
dithiothreitol, 2% sodium dodecyl sulfate (SDS), 10% glycerol, 0.2% bromphenolblue) and
separated by SDS–10% polyacrylamide gel electrophoresis (PAGE) [15].
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LC-MS/MS analysis
Proteins binding to the RNA coated beads were separated by size in a 10% SDSpolyacrylamide gel. The proteins bands of interest were visualized by colloidal Coomassie blue
and excised from the gels. The gel slices were digested with trypsin (2 μg/ml) overnight at 37oC.
The digested peptides were dried and reconstituted in 5% acetonitrile, 0.1% formic acid and then
loaded onto a C18 column using a helium pressure cell. Peptides were eluted from the column
using a linear acetonitrile gradient of 5-50% over 60 min with a flow rate 300 nl/min. The iontrap mass spectrometer (ThermoFinnigan LCQ Deca PLUS) was programmed to perform a full
MS scan followed by MS/MS scans of the five most abundant ions present. Raw data files were
compared to the Swiss-Pro database using SEQUEST software to identify proteins that match the
peptide fragments. Protein identification used very rigorous criteria to determine protein
identification. Peptides sequenced by LC MS/MS have three charged states (+1, +2, and +3) and
each charge state produces a unique spectrum. Only those peptides with a ΔCn greater then 0.1
regardless of the charge state were accepted except in those peptides with very strong XCorr
values. Peptides were accepted only if they meet the minimal XCorr scores of 1.9, 2.2, and 3.7
for the +1, +2, and +3 charge state peptides. Protein identifications were manually confirmed
[21].

Purification of RNA binding proteins
RNAs were covalently linked to adipic acid dihydrazide-agarose beads by a modification
of a published procedure [22,23]. Briefly, 1000 pmol of RNA were placed in a 400 μl reaction
mixture containing 100 mM sodium acetate, pH 5.0, and 5 mM sodium m-periodate (Sigma).
Reaction mixtures were incubated for 1 h in the dark at room temperature. The RNA was then
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ethanol-precipitated and resuspended in 500 μl of 0.1 M sodium acetate, pH 5.0. Adipic acid
dihydrazide-agarose beads (400 μl) (Sigma) were washed four times in 10 ml of 0.1 M sodium
acetate, pH 5.0, and pelleted after each wash at 300 rpm for 2 min in a clinical centrifuge. After
the final wash, 1000 μl of 0.1 M sodium acetate, pH 5.0, was added to the beads, and the slurry
was then mixed with the periodate-treated RNA and rotated for 12 h at 4 °C. The beads with the
bound RNA were pelleted and washed three times in 1 ml of 2 M NaCl and three times in 1 ml
of buffer (20 mM HEPES-KOH, pH 7.6, 10% v/v glycerol, 150mM M KCl, 0.2 mM EDTA) and
200 μg tRNA to block nonspecific protein binding to the beads. The beads containing
immobilized RNA were incubated in a reaction mixture containing 100-250 μg of HeLa cell
nuclear extract with 300 μl of, ATP (2.5 mM), MgCl2 (2.0 mM), tRNA (500 ng) and buffer for
30 min at 30°C. Beads were pelleted by centrifugation at 1000 rpm for 2 min and washed four
times with 1 ml of buffer. After the final centrifugation to sediment the beads at 13,000 g the
proteins bound to the immobilized RNA were eluted by 75 μl of 80 mM Tris-Cl, pH 6.8, 0.1 M
dithiothrieitol, 2% SDS, 10% glycerol and 0.2% bromophenol blue by heating for 5 min at 95oC.

Western Blot Analysis
Eluted proteins from the adipic acid dihydrazide-agarose beads bound to RNA
oligonucleotides were separated on an 10% SDS-polyacrylamide gel. Western blot analysis was
as previously described [24]. The primary antibodies against hnRNP K, L, I and A2/B1 were
obtained from ImmuQuest. Anti-mouse IgG2b (Zymed) and IgG (Bio-Rad) conjugated to
horseradish peroxidase were used as secondary antibodies to detect hnRNP K, I and L, A2/B1,
respectively. The immunocomplexes were detected by enhanced chemiluminescence (Pierce).
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Images were visualized with film (Pierce) and quantified by densitometry using ImageQuant
(Molecular Dynamics).

RESULTS
The nuclear extracts are commercially available from several sources and has provided a
good quality extract to analyze in vitro transcription reactions [14], DNA/protein interactions
[25], RNA-protein interactions [22], and protein-protein interactions [26]. In addition, HeLa cell
nuclear extracts have been found to support in vitro splicing assays [27]. HeLa cells are a very
well characterized cell line that seems to have the ability of producing high-quality nuclear
extracts. HeLa cells produce a very high quality nuclear extract that is capable of recapitulating
transcription, translation, splicing, and poly adenylation. In addition, HeLa cell nuclear extracts
are also commercially available and methods for using these nuclear extracts are worked out.
These nuclear extracts provide a good starting point for the characterization of proteins bound to
the exonic RNA regulatory sequence found within exon 12 of G6PD mRNA.
In order to characterize the binding of RNA binding proteins to the exon splicing silencer
sequence within exon 12 of G6PD, we performed UV crosslinking analysis with full-length exon
12 and HeLa cell nuclear extract (Figure 1A). Protein bands of approximately 37, 45, 50, 60,
and 75 kDa were observed (Figure 1B). The RNA-crosslinked proteins were digested with
proteinase K to determine if these bands were RNA-RNA or RNA-protein complexes and as
shown in Figure 1B, lane 5, and all protein bands were abolished in the presence of proteinase K
indicating that these bands were protein-RNA complexes and not RNA-RNA complexes. In
addition, protein bands observed at 75-100 kDa indicated by the asterisk seem to be artifacts of
the UV crosslinking assay, because they were not observed consistently throughout all
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experiments and were observed in an RNA probe containing regions of the KS+ vector (Figure
1C, lane 1). In addition, the binding of proteins to exon 12 was independent of ATP (1 mM) as
shown by the same pattern of proteins observed in the presence or absence of ATP (Figure 1C,
lane 2 vs. lane 3).
To further map the region of exon 12 involved in protein binding the first 37 and 47
nucleotides of exon 12 were deleted (Figure 1A). The exon 12Δ1 RNA was a deletion of the first
37 nucleotides of exon 12 and there was no observable difference in protein binding with this
RNA (Figure 1D). In addition, deletion of the first 47 nucleotides of exon 12, exon 12Δ2,
showed a similar pattern as compared to full-length exon 12 RNA. Therefore, the first 47
nucleotides were not involved in the RNA binding of proteins (Figure 1D).
Further mapping studies were required to precisely map the RNA element and therefore
RNA oligos were used. Non-overlapping oligos from nucleotides 50-93 were UV crosslinked
with HeLa cell nuclear extract (Figure 2A). A positive control oligo to an hnRNP A1 binding
site was designed [17]. This hnRNP A1 RNA oligo contains nucleotide 6 through 20 of an
hnRNP A1 consensus sequence (Figure 2A). In addition, to being a high affinity site for hnRNP
A1 other hnRNPs will also bind this sequence. Incubation of RNA oligos 5’ labeled with γ-P32ATP with or without HeLa cell nuclear extract results in the appearance of several unique
proteins bound for each oligo (Figure 2B). The ability of each RNA oligo to bind a unique set of
protein bands indicates the specificity of this assay using short RNA oligos. Across multiple
experiments several bands were consistently observed. The 50-64 nucleotide oligo bound
several proteins at 75, 55, 50, 45, and 40 kDa (Figure 2B) and all of these protein were decreased
in the presence of 100X unlabelled nucleotide 50-64 RNA oligo (lane 3, Figure 2B). The
nucleotide 65-79 RNA oligo binds several proteins at 100, 60, 37, and 30 kDa as shown in lane 5
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(Figure 2B). These proteins decrease in intensity in the presence of 100x unlabelled nucleotide
65-79 RNA oligo as shown in lane 6. The nucleotide 79-93 RNA oligo binds a series of bands at
75, 50, and 37 kDa (lane 8, Figure 2B). The most prominent band bound to this oligo is the 50
kDa band. All protein bands including the 50 kDa band decreased in intensity with 100 x
unlabelled 79-93 nucleotide RNA oligo.
Recent findings have shown that a region from nucleotides 43-72 contain an exonic RNA
regulatory sequence [12]. In addition exon 12 was shown to inhibit splicing suggesting that this
region from nucleotides 43-72 contains an exonic splicing silencer sequence. Protein
identification studies were performed in intact animals and these studies showed the differential
binding of three hnRNP proteins to nucleotides 50-79. The identification of hnRNP L, K, and
A2/B1 to this region suggests that these three proteins are involved in the constitutive splicing of
G6PD mRNA by an exonic splicing silencer element [28]. These three proteins were identified
by the differential binding of a 60 and a 37 kDa band that was referred to as A and B for
simplicity [28]. The binding of two similar size proteins is also observed in HeLa cell nuclear
extracts (Figure 1B, lane 4; 1D, lane 1; and 2B). At this point these two bands will be identified
and from now on as the 60 and 37 kDa band.
The proteins in the 60 and 37 kDa bands were purified using RNA-affinity purification
and identified by LC-MS/MS analysis. RNA oligos 50-64, 65-79, 79-93, non-specific oligo, and
an oligo containing 50-79 nucleotides were used in an RNA affinity assay (Figure 3). Each RNA
oligo was covalently bound to adipic acid beads and incubated with HeLa cell nuclear extract
(Figure 3). Proteins were separated with 10% SDS-PAGE analysis and protein bands were
visualized by SRYPO Ruby because of the sensitivity and compatibility with MS/MS analysis.
The first observation is the ability of the adipic-acid bead purification to recapitulate the pattern
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of protein binding observed in the UV crosslinking. The longer RNA oligo containing 30
nucleotides was used in order to decrease possible steric hindrance of proteins bound in close
proximity to the bead (Figure 3, lane 5). The nucleotide 50-79 oligo did increase protein
binding, and the pattern was similar to the 65-79 nucleotide RNA oligo, but the band intensity
was increased several fold as shown in three different experiments (Figure 3, lane 5 vs. lane 2).
The boxes show the region that was cut from the SDS gel and sequenced by LC MS/MS
analysis.
LC-MS/MS analysis determined that the 60 kDa band contained three positive protein
matches. The first protein identified was hnRNP K and hnRNP K was sequenced with greater
then 40% sequence coverage and over 20 unique peptides were identified in the MS/MS run
(Table 1). The second major protein was hnRNP I, also known as polyprimidine tract binding
protein. This protein was sequenced with greater then 20% sequence coverage and six unique
peptides were sequenced during the MS/MS run (Table 1). The final constituent was identified
as hnRNP L, however the MS/MS data was weak with only 10% sequence coverage and only 3
unique peptides were identified by the LC-MS/MS. However, each peptide score was greater
then the minimal scores needed for accurate protein determination. The ΔCn scores were greater
then 0.1 and the XCorr values were greater then 1.9, 2.2, or 3.7, with a charged state of +1, +2,
and +3.
The identification of the 37 kDa band revealed two hnRNP proteins referred to as hnRNP
A2/B1 and hnRNP E1. The hnRNP A2/B1 was sequenced by greater than 20% and eight unique
peptides were sequenced with high validity (Table 1). The hnRNP E1 protein was sequenced by
17% and four unique peptides were sequenced with high enough scores to consider this protein a
positive match (Table 1). Each peptide was screened rigorously to ensure proper protein
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identification and all peptide scores were within the desired range of 0.1 and 1.9, 2.2, or 3.7 for
+1, +2, or +3 charged state peptides for ΔCn and XCorr scores, respectively.
The RNA-affinity approach was used to purify those protein bands bound to the exonic
RNA regulatory element found within exon 12. To provide additional evidence on protein
binding, Western blot analysis using antibodies to detect hnRNP K, L, I, A2/B1 and a nonspecific hnRNP M protein bound to the entire regulatory sequence from nucleotides 43-72. The
protein identification from nucleotides 50-79 was carried out by LC MS/MS analysis and at this
same time we further characterized a small region from nucleotides 43-50 was involved in G6PD
mRNA splicing in an in vivo animal study. Therefore we validated that the proteins bound to
nucleotides 50-79 were identical to the proteins bound to nucleotides 43-72 of exon 12 (Figure
4). As hypothesized identical patterns of protein binding was observed with nucleotides 50-79
and 43-72 confirming the identity of hnRNP K, L, I, and A2/B1 to an exon sequence within exon
12. The negative control in these experiments was the 79-93 oligo. The RNA sequences from
nucleotides 43-72 and 79-93 were used in the RNA affinity purification of proteins prior to
Western analysis with antibodies directed against hnRNP K, L, I, A2/B1, and hnRNP M.
HnRNP K, L, I, and A2/B1 were only detected bound to nucleotides 43-72 and were not detected
bound to nucleotides 79-93 (Figure 4). In addition, an additional negative control was used to
determine the selectivity of this RNA affinity approach to purify non-specific proteins. An
additional hnRNP family member, hnRNP M, was used to show selectivity within the assay.
The protein hnRNP M consist of a subfamily of four isoforms (M1, M2, M3, and M4) that are
known to bind to poly G and poly U rich regions with high affinity and are known to affect RNA
transport [29] and RNA alternative splicing [30]. However, hnRNP M was not detected in
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Western analysis or in LC-MS/MS analysis confirming the specificity of this RNA-affinity
approach to purifying authentic RNA binding proteins.
In this report we have presented evidence that a modified approach to the adipic-acid
bead RNA affinity purification will allow the use of short RNA oligos to purify high affinity
RNA binding proteins. In addition, the proteins at 60 and 37 kDa bound to nucleotides 65-79
were similar to those proteins observed in the full-length exon 12. One major disadvantage of
this approach is the minimal length of the RNA oligos used in the assay. However, the ability of
this assay to differentiate between sequences confirms the usefulness of this assay to characterize
the molecular mechanisms of gene expression.

DISCUSSION
These experiments describe a technique to covalently link oxidized 15 nucleotide oligos
to adipic acid agarose beads for the purification of RNA binding proteins. Purification of RNA
binding proteins is fundamental in defining and characterizing molecular biological events.
Therefore, the development of a purification scheme using short RNA oligos will allow the
fundamental purification and characterization of RNA binding proteins important for RNA
processing. Compared to reports using sequences greater then 100 nucleotides, the short oligo
approach has the advantage of only purifying those specific proteins bound to the regulatory
element. Because most RNA elements, ESEs and ESS, are six to ten nucleotides in length
[31,32], the 15 nucleotide oligos are more likely to encompass the entire RNA regulatory
sequence. This approach is not without disadvantages. The major disadvantage of the 15
nucleotide approach is the low recovery of proteins as compared to larger oligos, for example the
30 nucleotide oligos.
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In higher eukaryotes, pre-mRNA splicing is under the control of both positive and
negative regulatory elements, located within exon or intron sequences. These sequences are
usually small sequence specific sequences (4-20 nucleotides in length). These sequences are
referred to as intronic or exonic splicing enhancers or silencers [33]. The exonic splicing
enhancer sequences are most commonly bound by the SR family of splicing activator proteins
[19,34,35]. The SR family of splicing activators is thought to enhance the interaction with
U2AF35/65 and U1snRNP. In addition SR proteins recruit splicing co-activators like the Srm160 protein to the spliceosome [36-38]. Our study did not identify any potential SR proteins
because of our methodology. In our experiments we used trypsin as a site specific protease to
cleave our proteins into peptides. SR proteins are arginine rich and would have been digested to
very small fragments by trypsin and therefore eluding detection via LC MS/MS. Other methods
including different proteases like Trypsin C which cleaves only at lysine residues could be used
in LC-MS/MS analysis. A recent published paper from Szeszel-Fedorowicz et al. has shown the
binding of SRp75 and potentially ASF/SF2 and/or SC35 to nucleotides 43-72 of exon 12 G6PD
mRNA by Western analysis [12].
Exon splicing silencer sequences (ESS) are known to function through binding of the
hnRNP proteins [33,39]. HnRNP proteins are a structurally diverse family of proteins originally
identified through their interaction with pre-mRNA [33,39]. Individual members of the hnRNP
family are known to have specific effects on RNA processing and function, including both
alternative and constitutive splicing [8,40]. The most common associated proteins to RNA are
the hnRNP A/B, hnRNP I (PTB), hnRNP K and the hnRNP H protein. These proteins are known
to repress splicing of many exons by binding to UAGG, UCUC, C-rich patches, and poly G
motifs, respectively. The identification of hnRNP K bound to region 43-72 nucleotides of exon
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12 revealed a strong C-rich patch consisting of two C-rich patches within 65-72 nucleotides of
exon 12. Further analysis of the sequence did not reveal any UAGG, UCUC, or poly G motifs
within the region of 43-72 nucleotides of exon 12. The interaction of hnRNP proteins with ESS
elements are thought to inhibit the spliceosome assembly complex [17,41,42]. Identification of
these proteins and many more unidentified proteins will increase the depth of knowledge about
splicing and their role in constitutive and alternative splicing events. Originally it was thought
that ESE sequences were more important but recent discoveries have concluded that ESS
sequences are more important. Once we have identified specific proteins bound to specific
sequences we can begin to understand the genomic and proteomic diversity within different cell
types. The identification of hnRNP K, L, I, A2/B1 bound to a region from 43-72 nucleotides of
exon 12 confirms our original hypothesis that exon 12 contains a cis-acting regulatory element
that we will now call an ESS. Further identification and characterization of this element and its
respective protein binding partners will be further characterized in HeLa cell nuclear extracts.
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Table 1: The identification of hnRNP K, L, I, A2/B1 and E2 is bound to the RNA element
within 50-79 nucleotides of exon 12. The 60 and 37 kDa bands were excised from the gel
digested with trypsin (2μg/ml), prior to peptide purification. Peptides were eluted from a C18
column using a 5-50% acetonitrile gradient. Each peptide with strong cross-correlation scores of
greater then 1.9, 2.7, and 3.7 for +1, +2, and +3 peptides, respectively and ΔCn scores greater
then 0.1 was considered a positive peptide match. Each peptide was then scanned using the
SEQUEST software analysis tool in order to determine protein IDs.
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Figure 1: Exon 12 binds several proteins from HeLa cells as detected with UV crosslinking (a)
The G6PD gene contains 13 exons and 12 introns. A series of RNAs was made to map the cisacting element responsible for protein binding. The full-length exon 12 contains 93 nucleotides
of exon 12, the exon12Δ1 contains region 37-93 nucleotides of exon 12 and exon 12Δ2 contains
region 47-93 nucleotides of exon 12. (b) Exon 12 RNA was incubated with or without HeLa
cell nuclear extracts and UV crosslinked as described in the materials and methods. Proteins
bound to the Exon 12 RNA element were abolished by the presence of proteinase K. This figure
is representative of six different nuclear extract experiments. (c) Protein binding was observed
in the presence of ATP (lane 2) compared to the absence of ATP (lane 3). (d) Full-length exon
12 and the two deletion probes were used to identify sequence specific protein binding. All
proteins were visualized by phosphor imager analysis. The series of protein bands bound to the
exon 12 RNA elements were consistently observed in two separate nuclear extract preparations.

Figure 2: The fine mapping of the exon 12 protein binding siteusing RNA oligonucleotides. (a)
The 15 nucleotides RNA oligos were designed to regions 50-93 nucleotides within exon 12. A
longer oligo was designed to nucleotides 50-79 of exon 12. The positive control RNA oligo is
referred to as the hnRNP A1 consensus oligo.

The non-specific oligo was a random 15

nucleotide oligo. (b) Each RNA oligo was mixed with HeLa cell nuclear extract and UV
crosslinked as described in Materials and Methods. Competitor was the same oligo, unlabeled,
and present at 100X concentration.The blots are representative of three different nuclear extract
preparations.
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Figure 3: RNA affinity purification of the 60 and 37 kDa protein bands bound to the RNA
element located within 65-79 nucleotides of exon 12. A series of RNA oligos were covalently
bound to adipic acid dihydrazide-agarose beads and used to purify the RNA bound proteins using
the bead pull-down approach. An additional RNA oligo was designed to represent nucleotides
50-79 of exon 12. The asterisks represent non-specific proteins observed in varying intensities in
all RNA oligos. The dotted boxes represent those bands that were manually excised from the gel
for LC-MS/MS analysis. Only the bands in the 50-79 nucleotide oligo were excised from the
gel. The bands labeled as A and B were 60 and 37 kDa, respectively and were consistently
observed in all experiments.

Figure 4: Confirmation of hnRNP K, L, I, and A2/B1 binding to a region of G6PD mRNA from
nucleotides 43-72 within exon 12. Two RNA oligos (nucleotides 43-72 and 79-93) were
covalently bound to the adipic acid dihydrazide-agarose beads and incubated with 100 μg of
HeLa cell nuclear extract in the presence of splicing conditions. The proteins were purified
using the bead pull-down approach and all proteins were separated on a 10%-SDS
polyacrylamide gel prior to western blotting. The input reflects 10% of the total HeLa cell
nuclear extract used in the assay.
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Summary
Nutrient regulation of glucose-6-phosphate dehydrogenase (G6PD) expression occurs
through changes in the rate of splicing of G6PD pre-mRNA. This posttranscriptional
mechanism accounts for the 12- to 15-fold increase in G6PD expression in livers of mice that
were starved and then refed a high-carbohydrate diet. Regulation of G6PD pre-mRNA splicing
requires a cis-acting element in exon 12 of the pre-mRNA. Using RNA probes to exon 12 and
nuclear extracts from livers of mice that were starved or refed, proteins of 60 kDa and 37 kDa
were detected bound to nucleotides 65-79 of exon 12 and this binding was decreased by 50%
with nuclear extracts from refed mice. The proteins were identified as hnRNP K, and L, and
hnRNP A2/B1 by LC-MS/MS. The decrease in binding of these proteins to exon 12 during
refeeding was not accompanied by a decrease in the total amount of these proteins in total
nuclear extract. HnRNPs K, L and A2/B1 have known roles in the regulation of mRNA
splicing. The decrease in binding of these proteins during treatments that increase G6PD
expression is consistent with a role for these proteins in the inhibition of G6PD mRNA
splicing.
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1. Introduction

The conversion of excess dietary energy to stored fuel via de novo fatty acid synthesis is
essential to energy homeostasis. Excess carbohydrate and protein in the diet are the primary
substrates for this pathway, which is most active in liver and adipose tissue. Fatty acid
synthesis involves a family of enzymes commonly referred to as lipogenic enzymes [1].
Lipogenic enzymes include glucose-6-phosphate dehydrogenase (G6PD), ATP-citrate lyase,
malic enzyme, acetyl-CoA carboxylase, and fatty acid synthase. Consistent with their role in
energy metabolism, the activities of these enzymes are induced when animals are fed a highcarbohydrate diet and decreased during starvation or by the addition of polyunsaturated fat to
the diet. The unique aspect of this dietary regulation is that the nutrients per se play a
significant role in the molecular mechanisms regulating the synthesis of these enzymes and in
the signal transduction pathways that mediate the change in nutritional status. While ATPcitrate lyase, acetyl-CoA carboxylase, fatty acid synthase, and malic enzyme are regulated by
changes in the transcriptional rate, G6PD is regulated solely by posttranscriptional mechanisms
[1, 2]. Posttranscriptional regulation has been proposed for malic enzyme and fatty acid
synthase [3-5], as well, indicating that nutrients regulate via multiple mechanism even for the
same gene.
Posttranscriptional regulation of mRNA abundance can occur at multiple steps during
RNA processing or through changes in the stability of the mature mRNA. The processing of a
nascent transcript includes addition of the 7-methylguanosine cap, 3’-end formation, and
splicing of all introns. Accurate processing is essential for the release of the mRNA from its
transcription site and for export of the mRNA to the cytoplasm [6]. Thus, efficient and
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complete maturation of mRNA is a potential control point in gene expression. Splicing of
mRNA requires distinguishing exons from introns. Within introns several sequences bind
components of the spliceosome; these include the 5' and 3' splice site, the branch point, and the
polypyrimidine tract [7]. Additional sequences in both the exons and introns function to
regulate the efficiency of splicing. Within exons, the splicing regulatory sequences are referred
to exonic splicing enhancers (ESE) and exonic splicing silencers (ESS) and these sequences
affect the recruitment of components of the spliceosome [7-9]. Introns contain analogous
regulatory sequences and these function to either enhance or block splice site recognition [10].
Families of serine-arginine rich proteins (SR proteins) and heterogeneous nuclear
ribonucleoproteins (hnRNPs) bind to these regulatory sequences. In general, SR proteins bind
ESEs and enhance splicing, while ESSs or their intronic counterparts are bound by hnRNPs
and splicing is silenced [8, 11-14]. Examples also exist of SR proteins inhibiting splicing and
hnRNPs enhancing splicing [15, 16]. Thus considerable research remains in order to
understand how cis-acting RNA elements and their binding proteins regulate splicing.
We characterized the posttranscriptional regulation of G6PD by dietary factors.
Refeeding mice after starvation causes a 12- to 15-fold increase in G6PD mRNA abundance in
the liver, while addition of polyunsaturated fatty acids to the diet or to the medium of primary
rat hepatocytes caused an 80% decrease in G6PD mRNA [17]. Despite this large change in
mRNA accumulation, the rate of transcription of the G6PD gene does not change. Rather, the
changes in G6PD mRNA abundance during refeeding of starved mice or by fatty acids are
caused by an in the rate of splicing of the primary transcript [18]. In this regard, changes in the
accumulation of the mature mRNA are preceded by changes in the rate of accumulation of
partially spliced mRNA in the absence of changes in polyadenylation or length of the poly (A)
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tail. If splicing is the regulated step, then sequences within G6PD RNA should be required for
this regulation. This hypothesis was tested by transfection of RNA reporter constructs into
primary rat hepatocytes. These constructs contained portions of the G6PD gene encoding the
pre-mRNA ligated to the CMV promoter, which is not regulated by nutrients. Expression of
RNA from this reporter was inhibited by treatment of the hepatocytes with fatty acids. Using
deletion mutagenesis of the reporter DNA a cis-acting element required for the control of
G6PD mRNA accumulation was localized to exon 12 of the G6PD pre-mRNA. Inclusion of
exon 12 and its surrounding introns was required for the inhibition of reporter RNA expression
by polyunsaturated fatty acids. Furthermore, this exon when ligated to a heterologous RNA
confers regulation by nutrients to this RNA [19]. These characteristics are consistent with
exon 12 containing an enhancer or a silencer element. Unique to this regulation is that it is the
rate of exon splicing that is regulated; G6PD mRNA is not alternatively spliced to form
different isoforms.
Constitutive exons are those always present in the mature mRNA. The regulated splicing
of G6PD mRNA involves a constitutive exon in this mRNA and a decrease in splicing of this
exon diminishes expression of this mRNA. This is a primary mechanism by which G6PD
expression is regulated [2]. Molecular mechanisms involved in the exclusion and inclusion of
alternatively spliced exons have been characterized. Little is known about the mechanism
regulating the rate of constitutive exon splicing particularly in response to hormonal or
nutritional factors.. The proteins involved in regulation of inclusion of alternatively spliced
exons may also be involved in the splicing of constitutive exons particularly those with weak
splice sites. To understand the molecular mechanisms involved in regulation of G65PD
splicing, we sought to identify the proteins that bind to exon 12 of G6PD mRNA. The large
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change in the accumulation of G6PD mRNA during the starvation to refeeding transition
makes this dietary paradigm ideal for the identification of regulatory proteins particularly those
whose binding might change in response to nutritional status. In this report, we present
evidence that hnRNPs K, L and A2/B1 bind to the exon 12 splicing regulatory element. A
region of G6PD exon 12 from nt 65-79 is sufficient to bind these proteins. The binding of
these proteins is enhanced by starvation and correlates with the decrease in G6PD mRNA
abundance in the livers of starved mice. These data are consistent with a role for these proteins
silencing the splicing of G6PD pre-mRNA. The identification of these regulatory proteins
provides new insight into the mechanisms by which nutrients control gene expression.

2. Materials and Methods

2.1. Animal Care

Four to six week old, male, C57BL/6 mice (Hill Top) were maintained on a highcarbohydrate diet with glucose as the carbohydrate source (Purina Mill) and supplemented with
1% (by weight) safflower oil (Sigma) as a source of essential fatty acids for seven days. On
day eight, the food was removed for a 24 h starvation period. At the end of the starvation
period, 10 mice were sacrificed and 10 were refed the high-carbohydrate diet for 24 h.

2.2. Plasmids and In vitro Transcription of RNA

111

The plasmid containing exon 12 of G6PD mRNA was generated by PCR using the 5’
primer AATAAGCTTTGATGAACTCAGGGA and the 3’ primer
ATTTCTAGACTGCCATATACATAG. The exon 11-13 plasmid was generated by
subcloning from a genomic clone following restriction digestion using Pst1 and Kpn1.
Exon12Δ1 probe (nt 37-93 of exon 12) was generated using PCR with the 5’ primer
ATAAAGCTTCTGCTGCACAAGATTGAT and the 3’ primer above. Exon12Δ2 probe (nt
47-93 of exon 12) was generated with the same 3’ primer and the 5’ primer
TGAAAGCTTATTGATCGAGAAAAGCC. All DNA inserts were subcloned into pKS+
plasmid using Hind III and Xba I sites created with the primers (Fig. 1A). RNA probes were
made using an in vitro transcription reaction with T3 RNA polymerase (Ambion) as previously
described [20].

2.3. RNA Oligonucleotides

RNA oligonucleotides corresponding to 15 or 30 nt regions of exon 12 (Fig. 1B) were
purchased from IDT (Coralville, IA). An RNA oligonucleotide, UAGGGACUUAGGGUG
(positions 6 to 20nt of a consensus sequence for hnRNP A1) was used as a positive control
[21]. As a negative control, an oligonucleotide, CAAAAGCAUGCAAAA, was designed to
lack known RNA regulatory elements as screened by the ESE and ESS finder databases:
http://exon.cshl.edu/ESE [22], http://genes.mit.edu/fas-ess [23], and
http://cubweb.biology.columbia.edu/pesx [24]. RNA oligonucleotides were end-labeled with
(γ-P32) ATP using a kinase Max kit (Ambion).
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2.4. UV Crosslinking

Nuclear extracts were prepared by the Dignam protocol [25]. Protein concentration was
measured by the Bradford assay. UV crosslinking reactions contained 5 to 10 µg of nuclear
extract protein, 10 to 20 fmol of substrate RNA (50,000 to 100,000 cpm), 1 mM ATP, 0.7 mM
MgCl2, and 40 ng of carrier tRNA in a 25 µl final volume of buffer (20 mM N-2hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) pH 7.9, 0.2 mM EDTA, 10%
glycerol, and 150 mM KCl) [26]. Reaction mixtures were incubated for 5 to 10 min at 30oC
and then subjected to UV crosslinking on ice for 10 min in a Stratalinker (1.8 x 106 µJ/cm2).
Samples were treated with (1 mg/ml) at 37oC for 30 min. Proteins were boiled for 5 min in
cracking buffer (80 mM Tris-Cl, pH 6.8, 0,1 M dithiothreitol, 2% sodium dodecyl sulfate
(SDS), 10% glycerol, and 0.2% bromophenol blue) and separated in 10% SDS-polyacrylamide
gels [26]. Binding of proteins to the RNA was visualized using storage phosphor imaging and
quantified using ImageQuaNT software.

2.5. RNA Affinity Purification of Binding Proteins

RNAs were covalently linked to adipic acid dihydrazide-agarose beads by a modification
of a published procedure [27, 28]. Briefly, 1000 pmol of RNA were placed in a 400 µl
reaction mixture (100 mM sodium acetate, pH 5.0, and 5 mM sodium m-periodate)and
incubated for 1 h in the dark at room temperature. Following ethanol-precipitated, the RNA
was resuspended in 500 µl of 0.1 M sodium acetate, pH 5.0. Adipic acid dihydrazide-agarose
beads (400 µl) (Sigma) were washed four times in 10 ml of 0.1 M sodium acetate, pH 5.0,
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resuspended in 1 ml of 0.1 M sodium acetate, pH 5.0 and mixed with the periodate-treated
RNA by rotation for 12 h at 4°C. The beads with the bound RNA were washed three times in
2 M NaCl and three times in 20 mM HEPES-KOH, pH 7.6, 10% v/v glycerol, 150 mM KCl,
0.2 mM EDTA and 200 µg/ml tRNA to block nonspecific protein binding to the beads. The
beads containing immobilized RNA were incubated with mouse liver nuclear extracts (100-500
µg protein) in 300 µl of 20 mM HEPES-KOH, pH 7.6, 10% v/v glycerol, 150 mM KCl, 0.2
mM EDTA plus 2.5 mM ATP, 2.0 mM MgCl2, 1000 ng/ml tRNA for 30 min at 30°C. Beads
were pelleted by centrifugation and washed four times with 1 ml of buffer without ATP, MgCl2
or tRNA. For one dimensional gels and Western analysis, the protein were eluted in 75 µl of 80
mM Tris-Cl, pH 6.8, 0.1 M dithiothreitol, 2% SDS, 10% glycerol, and 0.2% bromophenol blue
by heating for 5 min at 95 °C. For two-dimensional gel electrophoresis, the proteins were
eluted in 250 µl of 8M Urea, 2% Triton X-100, 1% dithiothreitol, 0.5% Pharmalyte, and
0.002% bromophenol blue for 2-3 h at room temperature.

2.6. Two-Dimensional Gel Electrophoresis

Proteins eluted from the beads were separated by isoelectric focusing (13 cm strips;
Amersham) with a pH range of 3.0 to 10.0 in the first dimension. The gels were hydrated by
incubation with the elution buffer containing the purified proteins for 12 h followed by
separation at 50 volts for 5 h, 100 volts for 2 h, 1000 volts for 2 h, 5000 volts for 2 h, 8000
volts for 6 h and maintained at 1000 volts for 4 h. The gels were then incubated in
equilibration buffer (50 mM Tris-Cl, pH 6.8, 6 M Urea, 20% glycerol, 2% SDS, 0.002%
bromophenol blue) plus 15 mg/ml of dithiothreitol for 15 min plus an additional 15 min in
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equilibration buffer plus iodoacetamide (18 mg/ml). The gels were placed horizontally onto an
SDS–10% polyacrylamide gel and run at 100 V for 6-8 h. For quantitation of the proteins, the
gels were stained with SYPRO Ruby using the manufacture's protocol and visualized using an
excitation of 450 nm and emission of 610 nm on a Typhoon Scanner (GE Healthcare). For
visualization of proteins prior to excision of protein spots, the gels were stained with colloidal
Coomassie blue (Invitrogen) and visualized under a light box. The visualized spots were
excised from the gel and stored at –80oC.

2.7. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis

Proteins binding to the RNA coated beads were separated by size in a 10% SDSpolyacrylamide gel. The proteins bands of interest were visualized by colloidal Coomassie
blue and excised from the gels. The gel slices were digested with trypsin (2 µg/ml) overnight
at 37oC. The digested peptides were dried and reconstituted in 5% acetonitrile, 0.1% formic
acid and then loaded onto a C18 column (ZipTip) using a helium pressure cell. Peptides were
eluted from the column using a linear acetonitrile gradient of 5-50% over 60 min with a flow
rate 300 nl/min. The ion-trap mass spectrometer (ThermoFinnigan LCQ Deca Plus) was
programmed to perform a full MS scan followed by MS/MS scans of the five most abundant
ions present. Raw data files were compared to the Swiss-Prot database (Version 47) using
SEQUEST software (Turbo) to identify proteins that match the sequence of the peptide
fragments. The criteria we used to determine the protein identity were a

Cn score of less than

0.1, regardless of the charge state and a cross correlation (Xcorr) score of at least 1.9, 2.2, or 3.7
for the +1, +2, or +3 charge states, respectively [29]. In a few cases, peptides with an
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Cn

score of greater than 0.1 were accepted if the Xcorr was strong. Protein identifications were
manually confirmed [30].

2.8. Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF)
Mass Spectrometry Analysis

Following separation in the two-dimensional gels, the colloidal Coomassie blue stained
gel pieces containing proteins were destained using a 1:1 ratio of 100 mM ammonium
bicarbonate and methanol for 30 min followed by 30 min with 100 mM ammonium
bicarbonate and acetonitrile for 10 min. The samples were dried under a vacuum and
rehydrated overnight in 2 µg/ml of trypsin in 25 mM ammonium bicarbonate at 37oC. The
samples were sonicated for 15 min in 2 volumes of acetonitrile. The peptides were purified
using a ZipTip C18 (Millipore) pre-equilibrated with 10% acetonitrile and 0.1% trifluoroacetic
acid. The samples were eluted from the ZipTip using 2% acetic acid and 50% acetonitrile
solution. The resulting sample was mixed with matrix (50 mM

-cyano-cinnamic acid in

49.5% ethanol, 49.5% acetonitrile and 0.0001% trifluoroacetic acid solution. The MALDI 96
well plate was spotted with 1 µl in each well and air-dried. The MALDI-TOF (Proteomics
Workflow) data was evaluated using the MASCOT software (2.1).

2.9. Western Blot Analysis

Eluted proteins from the adipic acid dihydrazide-agarose beads bound to RNA
oligonucleotides were separated on 10% SDS-polyacrylamide gel. Western analysis was as
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previously described [31]. The primary antibodies against hnRNP K, L and A2/B1 were
obtained from ImmuQuest. Anti-mouse IgG2b (Zymed) and IgG (Bio-Rad) conjugated to
horseradish peroxidase were used as secondary antibodies to detect hnRNP K, and L and
A2/B1, respectively. The immunocomplexes were detected by enhanced chemiluminescence
(Pierce). Images were visualized with film (Pierce) and quantified by densitometry using
ImageQuant (Molecular Dynamics).

3. Results

3.1. Starvation enhances binding of proteins to exon 12 RNA

Regulation of G6PD expression both in mouse liver and primary rat hepatocytes occurs
by changes in the rate of pre-mRNA splicing [18, 32]. Exon 12 contains a regulatory element
involved in regulated splicing of G6PD pre-mRNA [19]. Therefore, we used exon 12 as a
probe (Fig. 1A) in UV crosslinking assays with mouse liver nuclear extracts to identify RNA
binding proteins that may be involved in regulated splicing. Multiple proteins bound to exon
12 RNA. Unique bands were consistently observed at approximately 60 kDa, 50 kDa and 37
kDa (Fig. 2A, lane 1). Additional protein bands at 75 kDa and 150 kDa were not observed in
all experiments, and a 100 kDa band was observed with multiple RNA probes including the
transcribed multiple cloning site of pKS+ (data not shown). Thus, the 75, 100 and 150 kDa
bands were interpreted to be non-specific binding caused by UV crosslinking and such band
are not atypical of this assay (cf., Fig. 2A versus Fig. 5, first lane each panel). Multiple
controls were used to verify that the observed bands represented protein bound to the RNA
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(data not shown). Competition experiments with unlabelled exon 12 RNA probe were
performed. The bands at 60 kDa, 50 kDa, and 37 kDa were decreased by unlabelled RNA
probe in a concentration dependent manner. UV crosslinking of the RNA probe in the absence
of nuclear extract did not result in any bands. Furthermore, digestion of the RNA/protein
complex with proteinase K eliminated all bands verifying that they are bound protein and not
double stranded RNA molecules. Thus, the pattern of bands observed in this assay represents
proteins binding to the RNA probe.
The amount of protein binding to exon 12 varied with nutritional status of the mice.
Refeeding with a high-carbohydrate diet resulted in a decrease in the intensities of the protein
bands at 60 and 37 kDa. These bands designated as A and B, respectively, were decreased by
almost 50% (Fig. 2A compare lanes 1 and 5), and this decrease in protein binding exceeded the
minor differences in intensity observed with the non-specific band at 100 kDa. Furthermore,
the inhibition of binding was consistent across multiple nuclear extract preparations (Fig. 2B).
These nuclear extracts were prepared from intact livers. During refeeding, the amount of
glycogen in liver increases dramatically (25% increase in liver weight, [33]); glycogen can
contaminant cellular fractions. A remote possibility is that these differences in band intensity
reflect differences in the concentration of glycogen in the nuclear extract that artificially
affected protein binding. Purified glycogen (1 to 5 µg) was added to the UV crosslinking
reactions using the starved nuclear extracts. The pattern and intensity of protein binding was
not altered by the addition of glycogen (data not shown). In addition, silver staining of nuclear
extracts separated on polyacrylamide gels further confirmed that overall protein content was
similar between starved and refed extracts (data not shown). Thus these differences in protein
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binding between dietary states are consistent with the idea that these proteins at 60 and 37 kDa
are involved in the regulated splicing of G6PD mRNA.
We next asked if additional differences in protein binding or intensity would be observed
if we included the introns surrounding exon 12 in the RNA probe. Using a construct
containing exon 11 through 13 with surrounding introns, a similar pattern of protein bands was
observed as with exon 12 alone (Fig. 2A, lanes 2 and 6). A band at 55 kDa was unique to the
exon 11-13 RNA probe. Importantly, the decrease in protein binding at bands A and B during
refeeding was retained with this longer construct (Fig. 2B). The intensity of the band at 55
kDa did not vary across multiple experiments. Thus, starvation and refeeding cause major
differences in the binding of proteins to an exon involved in regulated splicing of G6PD premRNA.

3.2. The 60 kDa and 37 kDa proteins bind to nt 65-79 of exon 12.

To further localize the binding sites for the 60 kDa and 37 kDa proteins in bands A and
B, two RNA probes containing 5' deletions of exon 12 sequences were synthesized. These
probes had deletions of the first 37 and 47 nt from exon 12, respectively (Exon 12Δ1 and Exon
12 Δ2; Fig. 1A). The pattern of protein binding to these probes was the same as to the fulllength exon 12 (Fig. 2A, lanes 3 and 4). In addition, the decrease in binding at bands A and B
during refeeding was maintained in these shorter RNA probes (Fig. 2A, lanes 3 and 4 versus 7
and 8, and Fig. 2B). The first 37 nt of exon 12 are not required for regulated splicing of G6PD
mRNA in rat hepatocytes [19].

119

An RNA oligonucleotide approach was used to further localize the region of exon 12 that
binds the 60 and 37 kDa proteins. RNA oligonucleotides, 15 nt in length were synthesized
across sequence from 35-93 of exon 12 and were used in the UV crosslinking assay (Fig. 1B).
An oligonucleotide from 35-49 that overlaps with the 47 nt deletion above, functioned as a
negative control. Unique proteins bound to each RNA oligonucleotide (Fig. 3). Bands A and
B associated with full-length exon 12 were only observed with the oligonucleotide, nt 65-79
(Fig. 3). The intensity of bands A and B decreased in the nuclear extracts from livers of refed
mice, similar to the decrease observed with the full-length exon 12 RNA probe. Apparent
differences in protein binding observed with the other oligonucleotides (bands 1-6) were not
consistently observed in five separate crosslinking assays and with different preparations of
nuclear extracts. A positive control was designed to detect overall differences in protein
amounts between starved and refed nuclear extracts. Burd and Dreyfuss identified a 20 nt
sequence that is bound by hnRNP A1 as well as other members of the hnRNP family [21]. The
hnRNP A1 oligonucleotide was designed to contain nucleotides 6-20 of the Burd and Dreyfuss
sequence including the consensus UAGGGA sequence for hnRNP A1 binding [21]. In the UV
crosslinking assay, multiple bands were detected with the hnRNP A1 oligonucleotide including
an intense doublet at 37 kDa, corresponding in size to hnRNP A1 (Fig. 3). The intensity of the
bands did not differ between starved and refed nuclear extracts (n=12 nuclear extracts; data not
shown). An additional control was a non-specific oligonucleotide representing a random RNA
sequence that did not contain known binding sites for splicing regulatory proteins, as
determined using the databases indicated in Material and Methods. Binding of proteins to this
oligonucleotide was not detected (Fig. 3). These data further verify that the differences in
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protein binding between nuclear extracts from starved and refed mice are due to differences in
the interaction of the 60 kDa and 37 kDa proteins with nt 65-79.

3.3. RNA affinity purification of proteins binding to nt 65-79 of exon 12.

To determine the identity of the proteins in bands A and B, RNA oligonucleotides were
linked to adipic acid beads and used to purify proteins from the nuclear extract without
covalently linking them to the RNA. We first asked if this assay resulted in a similar pattern of
protein binding as the UV crosslinking assay. Proteins binding in the 60 and 37 kDa regions
(bands A and B, respectively) were detected with nt 65-79 (Fig. 4). The 60 kDa band was not
detected with nt 35-49, nt 50-64, nt 70-93 or the non-specific oligonucleotide. The 37 kDa
band was detected with nt 50-64, but not with nt 35-49, nt 79-93 or the non-specific
oligonucleotide. Proteins were not detected co-purifying with the beads alone (Fig. 4). As
observed with the UV crosslinking assay, the amount of proteins bound in bands A and B were
60% and 53% less, respectively in the nuclear extracts from refed mice. Thus, the assay
recapitulated the differences in protein binding at bands A and B observed with UV
crosslinking.
Steric hindrance between the short RNA oligonucleotides and the large beads could have
decreased overall protein binding. To facilitate maximum protein pull-down for identification
of the proteins with LC-MS/MS, a larger oligonucleotide spanning nt 50-79 of exon 12 was
used in the RNA affinity assay (Fig. 4). An identical pattern of proteins was observed with this
oligonucleotide as with nt 65-79; however, more protein per band bound to nt 50-79 and the
inhibition of protein binding in nuclear extracts from refed mice (51% and 44% for bands A
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and B, respectively) was maintained. The proteins bound to exon 12 were the same size as the
proteins bound to nt 50-79. To test if the bound proteins were the same, competition analysis
was used. The RNA oligonucleotide, nt 50-79 was used as a competitor in the UV crosslinking
assay with the full-length exon 12 as the probe (Fig. 5). Increasing amounts of unlabeled nt
50-79 were added to the reaction. This oligonucleotide effectively competed with the labeled
exon 12 probe for binding of the proteins in bands of A and B (Fig. 5, lane 1 versus lanes 2-4).
In contrast, the non-specific oligonucleotide was unable to compete with exon 12 for these
proteins (Fig. 5, lane 1 versus lanes 5-7). Thus, the region from nt 50-79 of exon 12 accounts
for the binding of the 60 kDa and 37 kDa proteins to the full-length exon.

3.4. HnRNPs K, L and A2/B1 bind to exon 12, and the binding is regulated by nutritional status.

The RNA affinity assay was used to purify the proteins in band A and band B in order to
determine their identity using LC-MS/MS. Only starved nuclear extract was used and the
reaction was increased five-fold to provide sufficient protein for the LC-MS/MS analysis.
Despite the increase in protein, the specificity of binding of the 60 kDa and 37 kDa proteins
(bands A and B) to nt 65-79 and nt 50-79 was retained (Fig. 6, lanes 3 and 6). Bands A and B
were excised from the gel and an in-gel digestion with trypsin was performed prior to LCMS/MS analysis (Fig. 6). Band A contained two proteins, hnRNP K and hnRNP L. The
percent sequence coverage of hnRNP K was 35.7% and 14 unique peptides were sequenced.
The coverage for hnRNP L was 33.2% with 16 unique peptides (Table 1). Band B contained
hnRNP A2/B1, which was identified based on sequence coverage of greater than 60% and with
21 unique peptides (Table 1). HnRNPs A2 and B1 are isoforms generated by alternative
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splicing and differ by 12 amino acids that are present in exon 2 of hnRNP B1 but not in hnRNP
A2 [34]. A manual search for a peptide containing this amino acid sequence yielded the
peptide, TLETVPL, with an Xcorr of 2.9 for a +2 charge-state peptide and a ΔCn value of
greater than 0.5. This peptide was from amino acids 4-12 of exon 2 and confirmed that hnRNP
B1 is in band B. Because both proteins share all other peptides, the occurrence of a peptide
unique to hnRNP B1 does not exclude hnRNP A2 from also being present in band B. The
molecular weight of the three identified proteins matched their mass predicted from the SDSpolyacrylamide gels. HnRNP C1/C2 was also identified in band B. Seven peptides of this
protein were sequenced and the percent sequence coverage was less then 20% making
identification of this protein inconclusive.
To verify these protein identifications and to determine if additional proteins bound to nt
50-79, the proteins eluted from the adipic-acid beads were resolved in two-dimensional gels
and identification of protein spots was performed by MALDI-TOF. Once again, the hnRNP
proteins K, L, and A2/B1 were detected bound to this sequence. Multiple spots corresponding
to hnRNP A2/B1 were observed. HnRNP A2 migrates at a more acid pH in 2 dimensional gels
[35]. Thus, this is consistent with both isoforms binding to the RNA element but the existence
of one isoforms versus the other cannot be determined by MALDI-TOF analysis. The
identifications of hnRNPs K, L and A2/B1 were based on sequence coverage of 45%, 24% and
55%, respectively. HnRNP C1/C2 was not detected in the two-dimensional analysis. Three
additional proteins, dematin, p47 and SAP 114 were also detected bound to nt 50-79 (Fig. 7;
asterisk). These proteins are not directly involved in regulation of RNA splicing. They may
have bound non-specifically to one of the proteins pulled-down by the RNA-linked beads, and
thus, their intensity was decreased in the refed samples because the amount of their interacting
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partner, possibly hnRNP K was also decreased. Additional proteins in the 2D gels were not
sequenced because their concentration was too low to permit positive protein identification.
Proteins of greater intensity in the refed nuclear extracts were not observed consistent with the
previous data using UV crosslinking and one-dimensional gel analysis after affinity
purification.
The identification of hnRNPs K, L, and A2/B1 was confirmed using Western blot
analysis. Antibodies against hnRNPs K and L detected bands at 65 kDa binding to
oligonucleotides 65-79 and 50-79 (Fig. 8). Although the predicted molecular mass of hnRNP
K is 50.9 kDa, it migrates in polyacrylamide gels at 65 kDa [36 and Immunoquest product
literature]. Little or no protein bound to either the beads alone, to the non-specific
oligonucleotide (Fig. 8), or to the oligonucleotide, nt 79-93 (data not shown). Furthermore,
refeeding decreased the binding of hnRNPs K and L to nt 50-79 by 70 ± 8 % and 62 ± 3 %,
respectively, for three separate pull-down assays.

HnRNP A2/B1 was detected as a broad

band at 37 kDa. The antibody detects both isoforms of this protein. The amount of hnRNP
A2/B1 bound was decreased by 70.1% (n=2 pull-down assays) in extracts from refed mice.
The amount of these proteins in the total nuclear extracts (Fig. 8, input) did not vary with
nutritional status. Thus, nutritional status regulates the binding of hnRNP K, L, and A2/B1 to a
region of exon 12 from nt 65-79 in the absence of a change in their nuclear concentration.

4. Discussion

Over half of all genes undergo alternative splicing either in response to hormonal,
developmental signals or in a tissue-specific manner. This process is highly regulated. An
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increasing number of genes have been identified whose expression is regulated by changes in
the rate of splicing of constitutive exons; G6PD is one such gene [2, 37-39]. Unique to the
regulated splicing of G6PD is that it occurs in response to nutritional cues [2]. In this regard,
the 12- to 15-fold increase in G6PD mRNA accumulation during the starvation to refeeding
transition is caused by comparable changes in the rate of RNA splicing [18]. This large change
in mRNA accumulation makes this an excellent dietary paradigm in which to study the
molecular details involved in regulated splicing. Our work has identified a cis-acting
regulatory element in exon 12 of the G6PD mRNA that is required for regulated splicing of
this RNA [19]. In this report, we present evidence that hnRNP K, L, and A2/B1 differentially
bind to exon 12 in response to starvation and refeeding.
The inverse correlation between increased binding of hnRNP K, L and A2/B1 to G6PD
mRNA and a decrease in the abundance of G6PD mRNA during starvation suggests that these
proteins function to inhibit G6PD splicing. Only a few regulatory proteins have been described
that function to inhibit RNA splicing and among these are hnRNP L and A2/B1. HnRNP L
binds to an ESS in the CD45 mRNA and silences inclusion of three alternatively spliced exons
within this RNA [14, 40]. In each alternatively spliced exon of CD45 pre-mRNA, hnRNP L
functions within a composite RNA regulatory element that also contains an ESE and a
regulatory sequence that facilitates splicing regulation in response to external stimuli. In
contrast to this splicing silencing activity of hnRNP L, this protein also functions to enhance
splicing of the nitric oxide synthase pre-mRNA [15]. HnRNPs of the A and B group function
in the inhibition of tat exon 1 splicing in the HIV-1 pre-mRNA [27, 41]. The different
isoforms within this group are equally effective in causing this inhibition. Because hnRNP A2
and B1 cross-reacted with the antibody used in the Western analysis (Fig. 8), the presence of
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both hnRNPs or just hnRNP B1 cannot be determined. None-the-less, the binding of this
group of hnRNPs to G6PD exon 12 is consistent with it functioning in the inhibition of G6PD
expression during starvation. A potential role for hnRNP K in inhibiting G6PD splicing is less
clear. HnRNP K has ubiquitous functions in RNA metabolism; its roles in RNA translation
and mRNA stability are the best-characterized [42]. The ability of hnRNP K to interact with
other proteins involved in RNA processing [43] suggests that it may have a permissive
function, recruiting proteins that directly interact with components of the spliceosome.
Sequence specific details by which these proteins bind to their RNA elements are not
clear. The sequence between nt 65 and 79 of exon 12 is the minimal sequence required for
binding of these proteins, while binding is enhanced by inclusion of the upstream 15 nt.
HnRNP L binds to CA repeats in the nitric oxide synthetase mRNA but this binding enhances
mRNA splicing [15]. HnRNP L binds to an ESS in the CD45 mRNA [14]. The G6PD
regulatory element does not resemble this sequence and neither of these elements scores highly
using software designed to search for splicing silencing elements. HnRNPs of the A/B family
are predicted to bind tandem UAG repeats [21, 44]. This sequence is not present in the G6PD
regulatory element. The G6PD regulatory sequence does score highly as a potential exonic
regulatory sequence using a new algorithm developed using computational analysis of 46,103
exons [45]. This is consistent with our most recent data demonstrating that the region from nt
43-72 of exon 12 is an ESS [46].
The nt 65-79 sequence in exon 12 of G6PD mRNA does contain two C-rich stretches,
predictive of hnRNP K binding sites [42]. Mutation of the three C's from nt 65-67 markedly
decreases the binding of all proteins to the RNA (Griffith, B.N. and Salati, L.M., unpublished
data) and corroborates the finding that hnRNP K binds to this element. HnRNP K interacts

126

with a large number of nuclear proteins involved in splicing including hnRNPs L and A2/B1
[43]. The observation that elimination of a potential hnRNP K binding site also decreased the
binding of hnRNPs L and A2/B1 is consistent with the idea that the binding of hnRNP K
facilitates the interaction of hnRNPs L and A2/B1. Because these in vitro assays eliminate
regulatory functions of nuclear structure on RNA/protein interactions, conclusions regarding
their role in regulated splicing cannot be made. The physiological relevance of the interaction
of these hnRNPs with the G6PD regulatory element must be tested directly; these experiments
are on-going in the laboratory.
Regulatory elements found within exons can act as splicing enhancers or silencers
depending on the proteins that bind these sequences. Most enhancers bind members of the SR
family of proteins, while silencers bind members of the hnRNP family [8, 11-14]. In general,
the binding of SR proteins to ESEs enhances the recruitment of spliceosome components to the
exon 12. SR protein binding might have been expected using nuclear extracts from refed mice.
Bands increasing in intensity were not observed nor were these proteins detected in the 2dimensional gels. Thus, these proteins either do not bind within this sequence or the amount
bound was below the limits of detection. Because hnRNPs L and A2/B1 are known to bind
ESSs and act as splicing silencers, the binding of these proteins to G6PD pre-mRNA is
consistent withthis element being an ESS [46].
Three additional proteins were also identified by MALDI-TOF analysis. Dematin is a
known actin filament bundling protein that is not known to play a role in splicing [47]. The
protein, p47 is similar to a zinc finger protein (Zfp462), but the function of this protein is not
known (Swiss-prot database). SAP 114 protein, is a subunit of the spliceosome referred to as
the spliceosome associated protein, but the molecular weight of this protein is 30 kDa and does
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not match the 60 kDa molecular weight observed in the gel and perhaps co-purified with
another protein [48]. Therefore, the significance of these three proteins is not clear at this
point.
The changes in binding of hnRNPs K, L and A2/B1 to exon 12 occurred in the absence of
changes in the total amount of these proteins in the nuclear extracts (Fig. 8). HnRNPs are
known to undergo posttranslational modifications such as phosphorylation [49, 50],
methylation [51, 52], and sumoylation [53]. In the case of hnRNP K, phosphorylation can
regulate RNA binding [49]. It is likely that posttranslational modifications control the binding
of hnRNP K, L, and A2/B1 to the RNA regulatory element within G6PD mRNA.
Phosphorylation can cause a shift in the mobility of proteins in two-dimensional gels [54]. A
shift was not observed suggesting that this is not the case. Determining the mechanism for
these changes in protein binding and how they regulate mRNA splicing is the subject of ongoing research in our laboratory. Determination of how hnRNP K, L and A2/B1 differentially
bind to the RNA regulatory element within exon 12 will be fundamental in the elucidation of
novel regulation mechanisms involved in the nutritional regulation of gene expression.
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Table 1:
Assigned identities of Proteins bound to the 50-79nt region of exon 12. The band A identification
determined two proteins hnRNP K and L as two key proteins within band A. The identification of the
proteins in band B identified hnRNP A2/B1 protein. The table represents the molecular weight of each
protein, the percent sequence coverage as well as the number of unique peptides sequenced for each protein.
Protein
Band A

Band B

Organism

Accession
#

Mass
(kDa)

Sequence
coverage

Unique
peptides

hnRNP L

Mouse

796275

60.4

33.2%

16

hnRNP K

Mouse

079555

50.9

35.7%

14

hnRNP A2/B1 Mouse

872591

37.4

60.1%

21
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Figure Legends

Fig. 1. The structure of the G6PD RNA probes used in the identification of RNA binding
proteins. (A) The G6PD gene contains 13 exons and 12 introns of which exon 12 is known to
regulate splicing in primary hepatocytes [19]. The exon 12 probe contained the entire exon 12
sequence. The Exon 11-13 probe included exons 11 and part of exon 13 and the surrounding
introns. The Exon 12Δ1 and Δ2 probes had 5' deletions of 37 and 47 nucleotides from the exon,
respectively. (B) The sequence from nt 35-93 is diagrammed. The lines beneath the sequence
indicate the sequence of 15 or 30 nt RNA oligonucleotides used in the UV crosslinking and
RNA affinity assays. An oligonucleotide (oligo) containing an hnRNP A1 binding site was
used as a positive control in these assays. The non-specific oligonucleotide represents a
random sequence of nucleotides predicted not to bind to RNA binding proteins.

Fig. 2. Detection of RNA binding proteins by UV crosslinking analysis. (A) Mice were
starved for 24 hrs and then half were refed a high-carbohydrate diet for an additional 24 hrs;
liver nuclear extracts were prepared and UV crosslinked to the exon 12 RNA probes
diagrammed in Fig. 1A. The bands indicated by asterisks indicate non-specific protein
binding. A and B refer to bands of 60 kDa and 37 kDa, respectively, that changed in intensity
between starved and refed mice. (B) The protein bands A and B were quantified using
ImageQuant software. The percent-decrease was calculated by dividing the phosphor imager
units from starved by the value from refed samples. The values represent the mean plus or
minus the standard error of six different nuclear extracts.
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Fig. 3. The 60 kDa and 37 kDa proteins regulated by starvation and refeeding bind to nt 65-79
of exon 12. Mouse liver nuclear extracts from the livers of mice that were starved (S) or refed
(R) were UV crosslinked to end-labeled RNA oligonucleotides (oligo) to the indicated regions
of exon 12 or to the uniformly labeled full-length exon 12 probe (Exon 12). The hnRNP A1
consensus sequence was included as a positive control. The non-specific (NS) oligonucleotide
is an RNA oligonucleotide that was designed to lack known sites for splicing factor binding. A
and B refer to the 60 kDa and the 37 kDa bands, respectively. The numbers 1-6 represent
protein bands unique to each oligonucleotide.

Fig. 4. RNA affinity assay to purify RNA binding proteins. RNA oligonucleotides (oligo)
were covalently linked to adipic acid beads and used to pull-down RNA binding proteins. The
region of exon 12 represented by each oligonucleotide is indicated under the gel. The RNA
bound beads were incubated with nuclear extracts (100 µg of protein) from the livers of starved
(S) and refed (R) mice. The eluted proteins were separated by size on an SDS polyacrylamide
gel and visualized using Sypro Ruby. A and B refer to the 60 kDa and 37 kDa proteins. Beads
alone were the adipic acid beads without linked RNA. The non-specific (NS) oligonucleotide
was a negative control.

Fig. 5. The 60 kDa and 37 kDa proteins binding to full-length exon 12 and nt 50-79 are the
same. The uniformly labeled exon 12 probe was incubated with mouse liver nuclear extract
from starved mice in the presence of 0, 100, 1000, and 10,000-fold Molar excess of competitor.
The first competitor was unlabeled nt 50-79, and the second competitor was the non-specific
(NS) RNA oligonucleotide.

138

Fig. 6. RNA affinity assay for LC-MS/MS identification of the proteins within bands A and B.
Adipic acid beads bound to the indicated RNA oligonucleotides were incubated with nuclear
extract (500 µg of protein) from starved mouse livers. The boxes represent the regions that
were excised from the gel prior to trypsin digestion. The input lane was 10% of the amount of
protein used in the RNA affinity assay. NS was the non-specific oligonucleotide.

Fig. 7. Confirmation of protein identities by two-dimensional gel electrophoresis and MALDITOF analysis. Liver nuclear extracts (500 µg of protein) from starved and refed mice were
incubated with adipic acid beads linked to the RNA oligonucleotide, nt 50-79. The purified
proteins were eluted from the beads and analyzed by isoelectric focusing in a pH gradient from
3 to 10 followed by size separation in 10% polyacrylamide. The image shown is a Sypro Ruby
stain of protein in the gel. Each spot was excised from the gel and protein identity was
determined using MALDI-TOF analysis and MASCOT software. The asterisks are p47,
dematin, and SAP 114.

Fig. 8. HnRNP L, K and A2/B1 differentially bind to the exon 12 RNA regulatory element in
starved versus refed mice. RNA oligonucleotides to nt 65-79, nt 50-79 of exon 12, or the nonspecific (NS) oligonucleotide were covalently linked to adipic acid beads and incubated with
mouse liver nuclear extracts (100 µg of protein) from starved (S) and refed (R) mice. The
proteins were eluted from the beads and 2 µl of eluted proteins were analyzed by Western
analysis using the indicated antibodies (IB). Beads alone were adipic acid beads without a
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linked RNA oligonucleotide. The input lane was 10% of the amount of nuclear extract used
the RNA affinity assay.
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Chapter 4
Differential binding of hnRNP K, L and A2/B1 to an
Exonic Splicing Silencer element located within exon 12
of Glucose-6-Phosphate Dehydrogenase mRNA
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DISCUSSION
G6PD is a gene that is essential in fatty acid metabolism. The production of NADPH by
the G6PD reaction is essential for the production of reducing equivalents required for the de
novo synthesis of fatty acids. This unique characteristic makes G6PD a lipogenic enzyme. The
regulation of G6PD by nutritional factors like polyunsaturated fatty acids is essential for
regulating fatty acid synthesis and therefore polyunsaturated fatty acids inhibits G6PD
expression [1-3]. However, G6PD is unique compared to other members of the lipogenic gene
family in that the regulation by polyunsaturated fatty acids does not occur via a transcriptional
mechanism [1-3]. G6PD seems to be solely regulated by a posttranscriptional mechanism. The
regulation of teh rate of splicing of G6PD is thought to be the sole mechanism to control gene
expression of G6PD in primary hepatocytes and intact liver. Previous work has shown that
G6PD contains an important cis-acting element within exon 12 that is responsible for the
regulation of polyunsaturated fatty acids [4-6]. Additional work has shown that intact animals
starved for 24 h mimic the same pattern of regulation observed in primary cells incubated with
polyunsaturated fatty acids. Therefore we hypothesized that a region within exon 12 was a
protein binding site for either SR proteins or hnRNP proteins and the regulation of these proteins
would regulate the rate of splicing of G6PD mRNA. Predominantly, these sequences have been
called exon splicing enhancer and silencer and are usually short sequences (4-20 nucleotides)
within exons [7].
Protein identification and characterization required the assembly of several techniques
around a well established nuclear extract. In order to identify these proteins we used HeLa cell
nuclear extracts a cervical cancer cell line that does not mimic the regulation of G6PD observed
in either primary cells or intact animals, but this cell line is the most useful for development of
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new techniques. HeLa cells were used to purify nuclear extracts capable of producing a fully
complement of proteins required for splicing, transcription, and translation. According to
already established methods we used UV crosslinking with HeLa cell nuclear extracts and exon
12 RNA probes to detect unique proteins bound to regions within exon 12. A series of protein
bands were detected bound to the full-length exon 12, Exon12Δ1, and Exon12Δ2. This informed
us that a cis-acting element within 47-93 nucleotides was required for protein binding. At this
time we established a method in the laboratory of using RNA oligos to further characterize the
binding site of proteins within exon 12 (ref). Therefore a series of 15 nucleotide oligos were
used to further characterize the protein specific sequences. The sequence that produced the
strongest pattern of protein binding was a region within 50-79 nucleotides of exon 12. This
sequence was then used in an RNA affinity purification method using adipic-acid dihydrazideagarose beads to purify RNA binding proteins. The proteins were later sequenced by LCMS/MS analysis and revealed the identification of hnRNP K, L, I, E1, and A2/B1 bound to
nucleotides 50-79 of exon 12. The protein identification was confirmed by Western blot analysis
with the exception of hnRNP E1.
The reason we focused our identification to the region of 50-79 nucleotides was because
we were characterizing the proteins bound to regions of exon 12 within intact animals. In
addition, we knew from previous studies that starvation and refeeding induced a 12-15 fold
change in G6PD mRNA expression. Therefore we set out to isolate nuclear extracts from these
two different paradigms and use these nuclear extracts to characterize the nature of proteins
bound to exon 12. Upon successful isolation of proteins we observed in starved versus refed
animals that the pattern of protein binding was similar in these two different nuclear extracts.
However, the intensity of these bands was dramatically different in starved versus refed animals.
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The two bands that we focused are attention on were at 60 kDa and 37 kDa. These two bands
changed consistently with respect to dietary manipulation of the mice in over twelve different
nuclear extract preparations. Further characterization of the binding site for these two protein
bands revealed a similar region as observed using the HeLa cell nuclear extracts. The region
from 50-79 nucleotides of exon 12 was able to recapitulate the same pattern of protein binding as
the full-length exon 12. In addition, this sequence was able to show the differential pattern of
protein binding. At this time we purified these two protein bands with the adipic acid
dihydrazide-agarose beads and found via LC-MS/MS analysis that hnRNP K, L and A2/B1 were
the major constituents of band A and B, respectively. This matched those previously described
proteins observed bound in HeLa cell nuclear extracts.
Proteins identification revealed three main proteins, hnRNP K, L, and A2/B1, that were
consistently observed in human and mouse nuclear extracts bound to a similar region within
exon 12. Based upon the information we know about hnRNP K, L, and A2/B1 these proteins act
more like exonic splicing silencer proteins and therefore we believe this sequence from
nucleotides 50-79 mimics an ESS both in vivo and in vitro studies. Further analysis of these
proteins in both HeLa cell nuclear extracts and mouse liver nuclear extracts will be conducted to
show the relationship between these proteins and the splicing efficiency of G6PD mRNA. Our
hypothesis is further modified to state that hnRNP K, L, A2/B1 differentially binds to G6PD
mRNA in the presence of intact animals starved and refed. The differential pattern of protein
binding does suggest that those hnRNPs are inhibiting the splicing efficiency of G6PD mRNA
splicing in animals starved for 24 h compared to those animals refed for 24 h. This is the first
report of hnRNP proteins regulating the constitutive splicing of G6PD mRNA in response to the
starvation/refeeding paradigm.
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Appendix I
Identification of RNA Binding Proteins in
Nuclear Extracts from Primary Rat Hepatocytes
Primary rat hepatocytes were isolated from rats starved for 24 h and platted on
collagen coated plates prior to treatment. The hepatocytes were treated with insulin (0.04
μM) plus or minus arachidonic acid (175 μM). The presence of arachidonic acid
decreases G6PD mRNA by more then 50% [1,2]. Nuclear Extracts were prepared from
cells after 24 h of treatment and incubated with exon 12 RNA oligos prior to UV
crosslinking [3,4]. The region of exon 12 from nucleotides 43-72 was recently identified
as an exon splicing silencer sequence involved in inhibition of G6PD expression by
arachidonic acid [5]. Therefore we generated RNA oligos from nucleotides 50-93 to
identify proteins binding within this region in primary rat hepatocytes (Figure 1B).
Proteins bound differed across nucleotides 50-64, 65-79, and 79-93. As with both HeLa
cells and primary rat hepatocytes, proteins of 60 and 37 kDa were observed with the oligo
to nucleotides 65-79. HnRNP K is know to bind to C-rich regions and the oligo from
nucleotides 65-79 has 2 strong C-rich patches [6-8] with 3 or more contiguous C residues.
These regions from nucleotides 65-67 and 71-73 were mutated to A’s. These RNA oligos
were UV crosslinked to primary hepatocytes nuclear extracts. The Δ65-67 oligo showed a
dramatic reduction in protein binding, but the Δ71-73 nucleotide oligo showed less of a
difference as compared to nucleotides 65-79 in extracts from primary rat hepatocytes. The
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smaller change in G6PD expression (50%) in hepatocytes treated with arachidonic acid
may make it impossible to detect changes in the proteins bound to sequences within exon
12 using UV crosslinking techniques.
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Appendix II
Additional data on identification of RNA binding
proteins in Mouse liver nuclear extracts
Mice were fed a low-fat diet (1% Safflower Oil w/w) and a high-fat diet (65% Safflower
Oil w/w) for a full week. The mice were sacrificed and mouse liver nuclear extracts were
isolated. This dietary paradigm results in a 2-4 fold inhibition of G6PD mRNA in those
mice fed a high-fat diet as compared to those mice fed a low-fat diet. The mouse liver
nuclear extracts from both low-fat and high-fat mice were UV crosslinked to the fulllength exon 12 probe. The visualization of bands resulted in the proteins at 25, 37, 45, 60,
and 100 kDa. The pattern of protein bands was similar to those bands originally observed
in starved and refed mice liver nuclear extracts [9]. The pattern of protein bands was
similar between low-fat and high-fat mice suggesting that the small change in G6PD
mRNA expression can not be determined with UV crosslinking assays. This same pattern
of protein binding was observed in three separate nuclear extract preparations.
The region of exon 12 from nucleotides 43-72 was recently identified as an exon
splicing silencer sequence involved in inhibition of G6PD expression by arachidonic acid
[5]. Therefore we generated RNA oligos from nucleotides 50-93 to identify proteins
binding within this region in mouse liver nuclear extracts (Figure 1A). Mouse liver
nuclear extracts were isolated from those mice that were starved for 24 h and those mice
that were refed for 24. This dietary paradigm results in greater then 12-15 fold changes in
the amount of G6PD mRNA expression [10,11]. The large change in G6PD mRNA
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accumulation causes a differential pattern of protein binding across nucleotides 65-79
within exon 12. Therefore, proteins bound differed across nucleotides 50-64, 65-79, and
79-93. The change in protein binding to nucleotides 65-79 is not due to an overall change
in protein concentration or a change in glycogen concentration [9] suggesting that this
change is responsible for the posttranscriptional regulation of G6PD mRNA.
Identification of these proteins bound to nucleotides 65-79 showed the presence of hnRNP
K, L, and A2/B1 according to LC-MS/MS analysis, MALDI-TOF analysis, and Western
analysis [9].
HnRNP K is known to bind to C-rich patches and the oligo from nucleotides 65-79
has 2 strong C-rich patches [6-8] with 3 or more contiguous C residues. These regions
from nucleotides 65-67 and 71-73 were mutated to A’s in the presence of nucleotides 6579. These RNA oligos were UV crosslinked to mouse liver nuclear extracts isolated from
starved and refed mice. The Δ65-67 oligo showed a dramatic reduction in protein binding,
but the Δ71-73 nucleotide oligo showed less of a difference as compared to nucleotides
65-79 in extracts from primary rat hepatocytes. The Δ71-73 abrogated the differential
pattern of protein binding whereas the Δ65-67 abolished any protein binding to
nucleotides 65-79. The protein binding of hnRNP K to mRNA occurs through a region
within hnRNP K referred to as the K-homology domain (KH) domain and current
information suggest that these KH domains mediate the binding to RNA sequences. The
robust change in protein binding by removing these three C’s does disrupt the binding site
of hnRNP K. Therefore mutations of these C’s abolish protein binding and purification of
RNA binding proteins by RNA affinity purification.
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Appendix III
Methods
Animal care
Male C57BL/6 mice (HILL TOP) 4 weeks old were adapted to a normal 12 hr light and
dark cycle for 7 days while maintained on a standard chow diet (Harlan Teklad). Mice
were switched to a fat-free diet with glucose as the carbohydrate source (PURINA MILL)
supplemented with 1% (by weight) safflower oil (SIGMA) as a source of essential fatty
acids. The diet was prepared fresh daily, and the safflower oil was stored under N2 to
minimize oxidation. Mice received the high carbohydrate, low fat diet ad libitum for 7
days.

a) Starved/Refed Paradigm ⎯ On day eight, the food was removed for a 24 h starvation
period (both starved and refed mice) followed by returning the diet for 24 h (refed mice).
b) High-fat/Low-fat Paradigm ⎯ Mice were trained to consume the low-fat basal diet (1%
polyunsaturated fatty acids in the form of safflower oil) or high-fat (basal diet plus 6%
safflower oil) diet for one week as previously described [11]. On day 8, all mice were
sacrificed at the beginning of the feeding cycle period.

Nuclear Extract Preparation
Mice were sacrificed and the livers of the mice were homogenized in buffer I (0.25
M sucrose, 60 mM KCl, 15 mM NaCl, 15 mM HEPES pH 7.4, 2 mM EDTA, 0.5 mM
EGTA, 0.15 mM Spermine, 0.5 mM Spermidine and 14 mM ß-mercaptoethanol) in a
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Dounce homogenizer. The livers were homogenized with 12 strokes of pestle B (loose)
and 12 strokes of pestle A (tight). The homogenizate was layered over buffer II (0.75 M
Sucrose, 60 mM KCl, 15 mM NaCl, 15 mM HEPES pH 7.4, 2 mM EDTA, 0.5 mM
EGTA, 0.15 mM Spermine, 0.5 mM Spermidine and 14 mM ß-mercaptoethanol) and
centrifuged at 100 g for 10 min at 4oC. The brownish-red pellet was resuspended with
buffer III (2.0 M Sucrose, 60 mM KCl, 15 mM NaCl, 15 mM HEPES pH 7.4, 0.1 mM
EDTA, 0.1 mM EGTA, 0.15 mM Spermine, 0.5 mM Spermidine and 14 mM ßmercaptoethanol) and the homogenate was layered over 1 ml of buffer III in a Beckman
polyallomer centrifuge tubes (Beckman) and centrifuged in an SW 50.1 ultracentrifuge
rotor at 120,000 x g for 1 hr 4 min at 4oC. The white pellet was resuspended in extraction
buffer from the Dignam protocol [3] with the previous mentioned modifications [4]. The
pellet was homogenized in a dounce homogenizer for 5 min and placed at 4oC for 30 min
followed by centrifugation at 10,000 g for 10 min at 4oC. The residual supernatant was
referred to as the nuclear extract. Protein concentration was measured by the Bradford
assay and the corresponding concentrations were in the range of 1 to 2 μg/μl. The nuclear
extracts were frozen and stored at –80oC. The quality of the nuclear extracts was
measured by silver stained 10% SDS-PAGE.

RNA Isolation
RNA isolated from the liver of mice that were starved and refed was stored in
RNAlater (Ambion). RNA was isolated from the liver by the method of Chomczynski and
Sacchi [12]. Briefly, the liver of the mice was homogenized using a polytron for 15 s
using short pulses in solution D (10 ml) [12]. The homogenate was mixed with 1 ml of 2
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M sodium acetate, pH 4.0, and 10 ml of water-saturated phenol (Fisher) and 2 ml of
chloroform/isoamyl alcohol (fisher) (49:1 ratio) and incubated for 15 min at 4oC. The
nucleic acid layer and the protein layer were separated by centrifugation for 30 min at
4,000 g at 4oC. The upper layer contained the RNA and was removed from the phenol
chloroform layer and precipitated by the addition of an equal volume of isopropanol and
stored at –20oC for 12 hrs followed by centrifugation at 5,000 g for 30 min at 4oC; the
residual pellet was washed in 70% ethanol and resuspended in DEPC-H20. The quality of
the RNA was determined by the 28 and 18s ratio as determined by gel electrophoresis.

Purification of RNA binding proteins
RNAs were covalently linked to adipic acid dihydrazide-agarose beads by modification
of a published procedure [13,14]. Briefly, 1000 pmol of RNA were placed in a 400 μl
reaction mixture containing 100 mM sodium acetate, pH 5.0, and 5 mM sodium mperiodate. Reaction mixtures were incubated for 1 h in the dark at room temperature. The
RNA was then ethanol-precipitated and resuspended in 500 μl of 0.1 M sodium acetate,
pH 5.0. Adipic acid dihydrazide-agarose beads (400 μl) (Sigma) were washed four times
in 10 ml of 0.1 M sodium acetate, pH 5.0. After the final wash, 1000 μl of 0.1 M sodium
acetate, pH 5.0, was added to the beads, and the slurry was then mixed with the periodatetreated RNA and rotated for 12 h at 4°C. The beads with the bound RNA were pelleted
and washed three times in 1 ml of 2 M NaCl and three times in 1 ml of buffer (20 mM
HEPES-KOH, pH 7.6, 10% v/v glycerol, 150 mM KCl, 0.2 mM EDTA) and 200 μg/ml
tRNA to block nonspecific protein binding to the beads. The beads containing
immobilized RNA were incubated in a reaction mixture containing 100 μg of HeLa cell
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nuclear extract with 300 μl of buffer (20 mM HEPES-KOH, pH 7.6, 10% v/v glycerol,
150 mM KCl, 0.2 mM EDTA) plus 2.5 mM ATP, 2.0 mM MgCl2, 1000 ng/ml tRNA for
30 min at 30°C. Beads were pelleted by centrifugation and washed four times with 1 ml of
buffer.

MS/MS analysis
Proteins binding to the RNA coated beads were separated by size in a 10%
polyacrylamide gel. The proteins bands of interest were visualized by Colloidal
Coomassie (Invitrogen) and excised from the gels. The gel slices were digested with
trypsin (2 μg/ml) overnight at 37oC. The digested peptides were dried and reconstituted in
5% acetonitrile, 0.1% formic Acid and then loaded onto a C18 column using a helium
pressure cell. Protein peptides were eluted from the column using a linear acetonitrile
gradient of 5-50% over 60 minutes with a flow rate 300 nL/minute. The ion-trap mass
spectrometer (ThermoFinnigan LCQ Deca PLUS) was programmed to perform a full MS
scan followed by MS/MS scans of the five most abundant ions present. Raw data files
were compared to the SwissPro database using SEQUEST software to identify proteins
that match the peptide fragments. Protein identifications were confirmed with manual
sequencing of the peptides.

Western Blot Analysis
Eluted proteins from the adipic acid dihydrazide-agarose beads bound to RNA oligos
were removed by SDS loading buffer (0.1 M dithiothreitol, 2% sodium dodecyl sulfate
(SDS), 80 mM Tris pH 6.8, 10% glycerol, 0.2% bromphenol blue). The proteins were
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loaded onto a 10% polyacrylamide gel and transferred to immunoblot PVDF membrane
(Bio-Rad) at 100 V for 1.5 h. The membranes were blocked in 5% nonfat dry milk
overnight at 4oC. The membranes were then incubated with primary antibody diluted in
5% bovine serum albumin for 1 h at RT. The primary antibodies against hnRNP A2/B1
and SR proteins were obtained from ImmuQuest. Antibodies conjugated to horseradish
peroxidase were used as a secondary antibody to detect hnRNP A2/B1 and SR proteins.
The immunocomplexes were detected by enhanced chemiluminescence (Pierce). Images
were visualized with film (Pierce) and quantified by densitometry using Image Quant TL
software (Molecular Dynamics).
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